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ABSTRACT 
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  Dioxins are commonly known as highly toxic compounds that are persistent organic 
pollutants. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the most potent dioxin congener,  
and dioxin-like products are formed during the incomplete combustion of organic 
compounds in the presence of chlorine (waste incineration, burning of various fuels and 
poorly controlled combustion sources). In 1997, the International Agency for Research on 
Cancer (IARC) classified TCDD as carcinogen.  
Prostate cancer (PC) is an extremely serious disease in dogs. PC also represents the 
most commonly diagnosed cancer in males in the Western world. In general, animal 
models of human cancer have evolved in attempts to capture the complexity of the 
human disease. In particular, as humans, the dogs are the only other mammals that 
develop PC. The canine prostate gland shares many morphological and functional 
similarities with the human prostate, so this specie represents thus an attractive model 
for the study of the prostatic disease in dogs. Consequently, to evaluate the biological 
effects of TCDD on prostate cancer, in this study we used human prostate cancer cell 
line, PC3.  Until now, very few data are present in literature about PC3 and TCDD 
exposure. It is known that in PC3 cell line, a hormone-independent prostate cancer cell 
line, TCDD induces cytochrome P450 (CYP) 1A1 and CYP1B1 via the aryl 
hydrocarbon receptor (AhR). This effect of TCDD could result in higher elimination 
rates of concomitant drugs metabolized by these particular CYP isoenzymes. 
Autophagy is a tightly regulated process playing a normal part in cell growth, 
development, and homeostasis and helping to maintain a balance between the synthesis, 
degradation, and subsequent recycling of cellular products through the degradation via 
the lysosome. Defects of autophagy machinery are responsible for pathogenesis of 
different diseases, including cancer. The role of autophagy in cancer is controversial. 
There is evidence that autophagy may play a critical role in cancer progression at later 
stages, such as dissemination and metastasis, which account for most cancer-associated 
deaths, whereas in other cases it clearly contributes to tumor suppression by inducing 
tumor cell death. So, the aim of this study is to evaluate the biological effects of TCDD 
exposure to a highly metastatic prostate cancer cell line, PC3.  
 The prostate cancer cell line PC3 was exposed to different concentrations of TCDD 
(0.1, 1 and 100 pg/ml) and after 24, 48, and 72 hours of exposure cell proliferation and  
viability, cell morphology and cell cycle analysis were performed. Also, autophagy was 
evaluated using the following: (a) detection of acidic vesicular organelles (AVOs) by 
acridine orange staining; (b) immunofluorescence analysis (IF) of LC3 (microtubule 
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associated light chain protein 3), one of the well-known autophagy markers; (c) LC3 
gene expression by real-time PCR; (d) study of autophagic flux by chloroquine (CQ) 
(10µM), autophagy inhibitor, by western blot; (e) study the expression of multiple genes 
involved in autophagy machinery by real-time PCR. 
  When compared with their relative controls, TCDD (100 pg/ml) exposure at 24, 48, 
and 72 hours caused the following: (1) significant increase of cell proliferation (CP) 
(CP24h =20.3%, CP48h =54.5% and CP72h =52.4%); (2) significant increase of cell 
population at S phase; (3) significant increase of autophagy demonstrated by (a) detection 
of AVOs; (b) LC3 IF positivity; (c) LC3 over expression (expression ratio24h =1.4, 
expression ratio48h =6.2 and expression ratio72h =11.4); (d) CQ increased LC3-II 
accumulation; (e) moreover, we demonstrated that the induction of autophagy by TCDD 
in PC3 cells was accompanied by an increase in the mRNA levels of certain genes that 
are present in different subnetworks composing the autophagy interactive network, such 
as: PIK3C3, BECN-1, AMBRA1, MAP1LC3B, ATG4A, ATG4C, ATG5, ATG7, 
ATG10, ATG16L1, GABARAPL1, PRKAA, WIPI-1. Also, we showed that TCDD 
negatively influenced genes that are autophagy inhibitor, such as: AKT1 and BCL2. 
These data suggested a multiple effect of TCDD on autophagy machinery. Furthermore, 
we revealed that TCDD exposure upregulated TNF whose high levels have been related 
to prostate cancer progression via stimulation of proliferation, survival of malignant cells 
and increased resistance to chemotherapeutic agents. 
From the 1980s, several illegal and uncontrolled sites of urban, toxic, and industrial 
waste disposal have been active in Campania region, Southern Italy, with the highest 
concentration reached in Naples and Caserta provinces. In 1994, Campania region is 
under a declared State of Emergency, because of the saturation of regional waste 
treatment facilities. There are growing national and international evidences that the 
accumulation of waste, illegal and legal, urban and industrial, has contaminated soil, 
water, and the air with a range of toxic pollutants including dioxins. A high correlation 
between incidences of cancer, respiratory illnesses, and genetic malformations and the 
presence of industrial and toxic waste landfills was also found. In Spring 2002, a dioxin 
emergency emerged in this region, as result of National Control Program of Residues in 
Foodstuff carried out by Health Minister in 2001, indeed, levels of TCDD exceeding the 
European Union tolerance were detected in dairy products and milk from cow and water 
buffalo, raised on in some areas of Campania Region. Cancer mortality descriptive 
studies demonstrated an increase of incidents rates of the prostate cancer in the same 
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areas where dioxin levels were elevated. Furthermore, studies performed in animal 
model suggested that TCDD exposure is associated with abnormal prostate 
development, altered prostate pathology and increase susceptibility to prostate cancer. 
The administration of TCDD to a variety of cultured cells may alter their ability to 
proliferate and die. In a previous study we demonstrated that TCDD induced 
proliferation in Madin-Darby Bovine Kidney (MDBK), an epithelial cell line, in which 
analysis of MDBK cell morphology revealed some alterations in a large number of 
exposed cells, where neither signs of apoptosis nor necrosis were detected, but we found 
that TCDD activated cell death with autophagy.  
Herein, TCDD exposure in PC3, a cancer cell line, induced no signs of cell death. 
So, taken together, our results support the idea that TCDD, may induce the progression 
of prostate cancer enhancing cell proliferation, inducing autophagy, deregulating the 
expression of genes related to the autophagy machinery, and upregulating TNF resulting 
in an increased risk for both animal and human health.  
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TCDD 
Dioxins are commonly known as highly toxic compounds that are persistent organic 
pollutants (POPs) for the environment. POPs include polychlorinated dibenzo-p-dioxins 
(PCDDs), polychlorinated dibenzofurans (PCDFs), non-ortho and mono-ortho 
polychlorinated biphenyls (PCBs).  
PCDDs or simply dioxins (but inaccurately), are derivatives of dibenzo-p-dioxin. 
There are 75 different congeners of PCDDs, and seven of them are specifically toxic 
(Pohjanvirta and Tuomisto, 1994). 
PCDDs consist of 12 carbon atoms, forming two aromatic phenyl rings attached to 
one another through two oxygen bridges,  and 8 other atoms that are attached to the 
molecule can be either hydrogens or chlorines (Fig. 1).  
 
  
Fig. 1. Chemical structure of PCDD 
 
Theoretically, 75 various combinations of hydrogen and chlorine are possible, and 
the resulting dibenzo-p-dioxin derivatives are called congeners. Chlorine increases the 
stability of these compounds, and chlorines in positions 2,3,7, and 8 (lateral chlorines) 
are especially important, because they are essential for toxicity and also prevention of 
enzymatic destruction of PCDDs (Fig.2). 
 
                         
Fig. 2. Chemical structure of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). 
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Therefore, the 7 congeners with 2,3,7,8-structure are toxicologically the most 
relevant. Each additional chlorine to 2,3,7,8-structure decreases toxicity, but the 
spectrum of adverse effects remains similar. Due to the fact that dioxin-like compounds 
normally exist in environmental and biological samples as complex mixtures of 
congeners, in mid-1980 the concept of toxic equivalents (TEQs) has been introduced to 
simplify risk assessment and regulatory control. In applying this concept, relative 
toxicities of dioxin-like compounds in relation to 2,3,7,8-TCDD (i.e. toxic equivalency 
factors, TEFs) are determined based on in vitro and in vivo studies. At 2,3,7,8-TCDD 
was assigned a TEF of 1.0 and all other congeners have lower TEF values ranging from 
0.5 to 0.00001. Calculating the toxic equivalency (TEQ) of a mixture involves 
multiplying the concentration of individual congeners by their respective TEF. The sum 
of the TEQ concentrations for the individual congeners is the TEQ concentration for the 
mixture. This approach is based on the evidence that there is a common, receptor-
mediated mechanism of action for these compounds, but it has its limitations due to a 
number of simplifications. The most important limitation is that the combined toxic 
effects of the components of a given mixture would be additive, neglecting possible 
synergism or antagonism. It should be recognized that revisions to the TEFs are 
periodically considered as new scientific information becomes available. If revisions in 
the TEFs are adopted, then it would be appropriate to adjust the TEQ release estimates 
calculated in the inventory (Birnbaum and DeVito, 1995). 
  
Physical Properties of TCDD 
TCDD is colorless, solid with no distinguishable odor. This compound is insoluble 
in water and soluble in organic solvents and lipids. It is resistant to acids and alkalis, and 
chemically degradable in few days by UV rays, in the presence of hydrogen ions donors 
(for example, in contact with the green foliage of plants). While, if present on a ground, 
it binds to the organic materials and it is degraded over months or years (Calkosinski et 
al., 2006).                 
                   
                    Sources of TCDD 
Microparticles of dioxins are found everywhere in the environment including the 
Arctic. TCDD and dioxin-like products are formed during the incomplete combustion of 
organic compounds (C, H, O), in the presence of chlorine. These can include waste 
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incineration (such as municipal solid waste, sewage sludge, medical waste and 
hazardous wastes), burning of various fuels (such as coal, wood, and petroleum 
products), other high temperature sources (such as cement kilns), and poorly controlled 
combustion sources (such as building fires). Dioxins can be formed during various types 
of primary and secondary metals operations including iron ore sintering, steel 
production, scrap metal recovery and formed as by-products from the manufacture of 
chlorine bleached wood pulp, chlorinated phenols (e.g., pentachlorophenol - PCP), 
PCBs, phenoxy herbicides (e.g., 2,4,5-T), and chlorinated aliphatic compounds (e.g., 
ethylene dichloride) (Clark et al., 1992) (Fig. 3). Since the TCDD is formed during the 
process of combustion of materials containing chlorine at temperatures lower than 800° 
C, the plants incineration  must use combustion systems at temperatures not lower than 
850° C for a sufficient time to complete destruction of products such as dioxins 
(Gribble, 1994). 
 
 
 
Fig. 3. Dioxin emission sources in percentage (Dobrzyński, Całkosiński et al. 2009) 
 
 Dioxins penetrate the human body mainly by ingestion of contaminated food with a 
high concentration of animal fat, by inhalation of contaminated air or by penetration 
through the skin (Mandal, 2005). Dioxin infiltration is facilitated by their liposolubility. 
More then 80% of accumulated dioxins are derived from food. A study showed that 
dioxins accumulated in human and animal fat tissues, and their elimination depends on 
life expectancy and the rate of metabolic processes. In humans, this period is about 9 
years. Elimination of these compounds depends on the number of chlorine atoms present 
in dioxin’s congeners. A significant amount of dioxin is removed from the body with 
milk during lactation. As presented by some authors, this may result in an overdose 
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(even 50-70 times higher) of dioxin concentration in mother’s milk. Dioxin 
concentrations in human tissue depend on diet and lifestyle. Dioxin in the human body is 
transported by lipids in blood serum to the liver and fat tissue, where it accumulates 
(Dobrzyński et al., 2009) (Fig.4). 
 
Fig. 4. Sources of natural environmental contamination (Dobrzyński, Całkosiński et al. 2009). 
 
                    Mechanism of action of TCDD 
The mechanism of action by which TCDD exerts the biochemical effects on 
vertebrate species is through the activation of the aryl hydrocarbon receptor (AhR)-
mediated signal transduction pathway. AhR is a ligand-activated basic helix–loop–helix 
transcription factor, and a member of the PER-ARNT-SIM (PAS) superfamily of 
transcription factors. After the binding of TCDD to the AhR in the cytosol, the complex 
heterodimerizes with the aryl hydrocarbon nuclear translocator (ARNT). The TCDD-
AhR-ARNT binding complex recognizes specific dioxin response elements (DRE) in the 
nucleus, leading to the expression of genes such as CYP1A1, CYP1A2, and CYP1B1 
(Whitlock, 1999; Nebert et al., 2000) (Fig.5). 
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Figure 5: TCDD mechansm’s of action inside the cell (Mandal 2005) 
 
Persistent activation of the AhR is likely responsible for toxic responses of TCDD 
in experimental animals and humans. In rodents a wasting syndrome, 
immunosuppression, teratogenicity, chloracne, and carcinogenicity/tumor promotion 
have been well studied. There is good evidence for an involvement for the AhR in these 
responses. However, the chain of events from receptor activation to the diverse toxic 
endpoints is largely unknown. 
 Alteration of growth and differentiation of epithelial tissues may underlie most of 
the toxic responses. 
 Furthermore, AhR regulates the transcription of CYP1A1, -1A2 and -1B1 that 
induce the drug metabolism. These enzymes may metabolize the drug to an inactive 
compound, in which case the drug would not evoke the desired effect. Alternatively, the 
drug may be activated to a harmful intermediate and cause adverse reactions and therapy 
may be compromised. (Bock, 1994; Ramadoss et al., 2005). 
  
                      TCDD CONTAMINATION INCIDENTS 
The first episodes of accidental contamination can be found in the early '30s, when 
Monsanto chemical industry in Alabama, started producing PCBs as byproducts. The 
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workers of Monsanto were exposed to TCDD and developed chloracne, associated with 
other symptoms such as loss of appetite, loss of libido and a general sense of fatigue. 
Documented accidents involving TCDD, date back to the 1960’s, during the 
Vietnam War, during which TCDD was produced as a byproduct of the Agent Orange, a 
herbicide defoliant that was sprayed extensively by US military forces. The results seen 
when several of the soldiers were exposed to the herbicide, through the skin or ingestion 
of water contaminated with it present, were tumors, malformations in progeny and 
significant increase in the incidence of diabetes (Michalek et al., 1998).  
The first Italian accident took place in Seveso. On July 10
th
 1976, there was an 
explosion of a safety valve of a reactor in the factory ICMESA Meda. This accident 
released massive amount of a toxic cloud containing TCDD, contaminating an area of 15 
square kilometers where 37,000 people lived. Extensive studies in the affected 
population are still continuing to determine the long-term human health effects from this 
incident. However, these investigations are hampered by the lack of appropriate 
exposure assessments. Chloracne was the only effect linked with sufficient certainty to 
dioxin exposure but increased risks of different types of cancer, 
cardiovascular/endocrine effects, as well as, reproductive defects were reported in the 
Seveso population (Pesatori et al., 2003). 
A case of TCDD contamination in food occurred in the United States of America in 
1997. Chickens, eggs, and catfish were contaminated with dioxins when a tainted 
ingredient (bentonite/ball clay) was used in the manufacture of animal feed.  
In 1999, high levels of dioxins were found in poultry and eggs from Belgium. 
Subsequently, dioxin-contaminated animal-based food (poultry, eggs, pork), were 
detected in several other countries. The cause was traced to animal feed contaminated 
with illegally disposed PCB-based waste industrial oil (Source: WHO registry). 
One of the most recent known incidents of human exposure and a good example of 
acute dioxin toxicity happened in late 2004. The former president of Ukraine Viktor 
Andriyovych Yushchenko was victim of an assassination attempt during his election 
campaign. Following an ingestion of hazardous amounts of TCDD, he developed 
chloracne (Sorg et al., 2009) (Fig. 6). 
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Figure 6: President Andriyovych Yushchenko before (left) and after (right) TCDD exposure. 
 
Since the 1980s, several illegal and uncontrolled sites of urban, toxic, and industrial 
waste disposal have been active in Campania region, Southern Italy, with the highest 
concentration reached in Naples and Caserta provinces (Barba et al., 2011). 
Since 1994, the region of Campania in south-west Italy is under a declared State of 
Emergency, because of the saturation of regional waste treatment facilities. There are 
growing national and international evidences that the accumulation of waste, illegal and 
legal, urban and industrial, has contaminated soil, water, and the air with a range of toxic 
pollutants including dioxins. A high correlation between incidences of cancer, 
respiratory illnesses, and genetic malformations and the presence of industrial and toxic 
waste landfills was also found (Barba et al., 2011). In Spring 2002, a dioxin emergency 
emerged in this region, as result of National Control Program of Residues in Foodstuff 
carried out by Health Minister in 2001 (Reg.CE 2375/01). It was demonstrated that 
levels of TCDD exceeding the European Union tolerance were detected in dairy 
products and milk from cow and water buffalo, in some areas of Campania Region 
(South Italy) (Diletti et al., 2003; Santelli et al., 2006).   
In July 2007, the European Commission issued a health warning to its Member 
States after high levels of TCDD were detected in a food additive - guar gum - used as 
thickener in small quantities in meat, dairy, dessert or delicatessen products. The source 
was traced to guar gum from India that was contaminated with pentachlorophenol 
(PCP), a pesticide no longer in use. PCP contains dioxins as contamination. 
Between the month of October and the month of February of 2008 it was an alarm 
for  levels of TCDD exceeding the European Union tolerance found in some sample of 
milk and mozzarella  in dairies of different areas of Campania region. Following, in late 
2008, Ireland recalled many tons of pork meat/products containing over 200 times more 
TCDD over the safe limits. This finding led to one of the largest food recalls related to a 
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chemical contamination. Risk assessments performed by Ireland indicated no public 
health concern (Source: WHO registry). 
 
TOXIC EFFECTS OF DIOXINS  
                    Animal Model Health Effects  
 TCDD showed a wide range of severe effects in animal experiments, including 
immunotoxicity, developmental and reproductive toxicity, teratogenicity, and 
carcinogenicity (DeVito et al. 1995). In particular, TCDD toxicity affects the immune 
system, increasing susceptibility to infectious diseases (viruses, various bacteria and 
parasites) (Burleson et al., 1996). 
 Exposure to TCDD during development has been extensively studied in mice, and 
can result in a number of different types of toxic effects, including: idronephrosis of the 
kidney (Abbott et al., 1987); cleft palate (Birnbaumn and DeVito, 1985); cardiac 
hypertrophy (Thackaberry et al., 2005); reduced cardiocyte proliferation (Thackaberry et 
al., 2005); suppressed immune response (Vorderstrasse et al., 2006); thymic atrophy 
(Staples et al., 1998); inihibition of prostate devolopment (Fritz et al., 2005); decresed 
epididymal sperm numbers (Theobald and Peterson, 1997); impaired learning ability 
(Powers et al., 2005); abnormal mammary gland formation (Vorderstrasse et al., 2004); 
altered keratinocy terminal differentation (Loertscher et al., 2002); increased relative 
liver weight (Lin et al., 2001). 
     It is well known that TCDD induces cancer in rats, mice, and hamsters (Huff et al., 
1994)(International Agency for Research on Cancer, IARC 1997). Oncogenic response 
in laboratory animals has been shown to depend on age, sex, species, dose, and route of 
administration (National Toxicology, 1982). 
     The association between TCDD exposure and breast cancer risk in animal models 
have also revealed contradictory findings. Some studies (Brown et al., 1998) have 
demonstrated that TCDD increases the number of DMBA-or MNU-induced mammary 
tumour in rats. In the other hand, others claim that TCDD is chemopreventive against 
spontaneous breast cancer (Safe et al., 1991, Greenlee et al., 2001).  
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     Animal Health Effects 
      In the last years several farms of cattles, river buffalos and sheeps in some areas of 
Campania Region (South Italy), have been unable to sell milk due to the presence of 
high levels of dioxins (Diletti et al., 2003; Santelli et al., 2006).   
From a study of Iannuzzi et al. 2004, several cases of abortion (around 25% of total 
births), abnormal fetus (2.5% of total births) and increased frequencies of chromosome 
abnormalities and fragments and sister chromatid exchange were recorded in two flocks 
of sheeps raised in the province of Naples where a higher level of dioxins were found in 
the milk mass (Iannuzzi et al., 2004). 
 
                     Human Health Effects 
Exposure to TCDD can result in a number of toxic effects in several species. In 
humans, one of the most commonly reported toxic effect is chloracne. Dioxin is also 
classified as carcinogen by the IARC, based on limited evidence of carcinogenicity in 
humans, but sufficient evidence in animals and mechanistic data (IARC, 1997).  
Descriptive studies on cancer mortality and congenital anomalies confirmed the 
presence of marked excesses mostly in the same areas where dioxin levels were 
elevated. In details, it has been demonstrated increase of incidents rates of the following: 
lung cancer in men and in women (Griffith et al., 1989; Goldberg et al., 1995), bladder 
cancer (Budnick et al., 1984; Griffith et al., 1989; Mallin, 1990), leukemia (Lotz et al., 
1991), childhood leukemia (Cutler et al., 1986), liver cancer in men (Goldberg et al., 
1995), prostate cancer (Goldberg et al., 1995), gastric cancer (Griffith et al., 1989, 
Goldberg et al., 1995), uterine cancer (Goldberg et al., 1995), rectum and breast cancer 
(Griffith et al., 1989), perinatal mortality and birth defects (Comba et al., 2006). The 
association between TCDD exposure and breast cancer risk has been inconclusive 
among different epidemiological studies  (Manz et al., 1991; Warner et al., 2002), and 
animal models have also revealed contradictory findings (Safe et al., 1991; Brown et al., 
1998). 
More effects are summarized in the U.S. Environmental Protection Agency (US 
EPA's)  draft exposure and human health reassessment of TCDD, and include peripheral 
nerve dysfunction, hepatic toxicity (increased liver size, hepatic enzyme changes), 
altered thyroid function in infants, altered hormone levels, developmental toxicity 
(decreased immune function),  possible effects on organs (heart, lung, kidney) (US EPA, 
2003). Other effects are spontaneous abortions (Bisanti et al., 1980), cytogenetic 
18  
 
abnormalities (Tenchini et al., 1983), congenital malformations (Rehder  et al., 1978) 
and immunological (Knutsen, 1984) and neurological impairments (Barbieri et al. 1988). 
 
                    In Vitro Effects 
The mechanism of action by which TCDD exerts the biochemical effects on 
vertebrate species is through the activation of the aryl hydrocarbon receptor (AhR) 
(Dobrzyński et al., 2009) and a number of studies suggest that AhR itself is directly 
involved in the regulation of carcinogenesis. The constitutively active AhR mutant has 
been shown to produce tumors of stomach and liver (Andersson et al., 2002; Moennikes 
et al., 2004), while the unliganded AhR has been suggested to function as a tumor 
suppressor (Fan et al., 2010). Thus, the activation of AhR might play a much wider role 
in carcinogenesis than a simple transcriptional control of CYP enzymes. 
One of TCDD effects in certain species is tumor promotion which is associated with 
alteration of differentiation and proliferation, TCDD-induced dysregulation of cellular 
growth and differentiation may be a possible mechanism of carcinogenesis. TCDD may 
activate the transcription of genes associated with cell proliferation through the TCDD 
responsive receptor/ enhancer system. Alternatively, this system may play a role in 
inhibiting the expression of genes normally suppressing cell division (Whitlock, 1990). 
 TCDD-dependent alteration of growth factors appears specific by species, tissues 
and developing stage. TCDD-induced toxicity and the subsequent compensatory cell 
proliferation may contribute to the induction of neoplasia.  
In colon cancer cell lines, H508 and SNU-C4, TCDD stimulated a dose-dependent 
increase in cell proliferation and  induced dose- and time-dependent phosphorylation of 
EGFR and ERK1/2 (Xie et al., 2012).  
In breast cancer cell line, MCF-7, TCDD stimulated cell proliferation and 
inactivated Akt, increased cdc25C/cdc2 activity, decreased P21/P27 activity, and 
enriched G2/M phase (Chen et al., 2012).  
The PI3K/PDK1/Akt signaling cascade mediates a variety of survival and 
proliferation responses. More recently, TCDD was found to activate and initiate 
plasmacytic differentiation of B lymphocytes through interfering Akt phosphorylation 
(North et al., 2010). Furthemore, it was demostarted that TCDD on PI3K/Akt signaling 
pathway in MCF-7 cells, dramatically decreased the phosphorylation of Akt (Thr308 
and Ser473) (Chen et al., 2012). 
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                       PROSTATE CANCER  
 
The prostate is a lobed gland that in male located at the junction of the bladder and 
the urethra. It contributes a liquid component to seminal fluid. The dog is the only 
species than man that spontaneously develops PC and many of the features of the 
disease in the dog are similar to its human counterpart. It has therefore been considered 
as a model for studing pathogenesis (Winkler et al., 2005; Winkler et al., 2006), 
treatment (Huang et al., 2005) and prevention (Waters et al., 2003). However a number 
of aspects of the pathogenesis, diagnosis and management of the disease are different 
between dogs and people (Starkey et al., 2005). 
PC is an uncommon disease in the dogs, with prevalence between 0.2 to 0.6% (Bell 
et al., 1991) and it is an extremely serious disease that can affect male dogs of all breeds 
and ages, whether intact or neutered, although it occurs more frequently in older dogs 
(9-10 years)(Cooley and Waters, 2001). 
Neoplastic prostate glands are often significantly and asymmetrically enlarged and 
may impinge on abdominal organs causing faecal tenesmus and dysuria. Haematuria, 
anorexia and weight loss may also occur. Some dogs may present signs of myelopathy 
or lameness that are manifestations of skeletal metastases. Indeed, PC is highly invasive, 
space-occupying masses that typically have metastasized by the time they are diagnosed. 
Commonly, PC given to metastasis to lumbar lymph-nodes, both inner and outer, to the 
vertebral body and lungs. The other targets for metastasis are the bladder neck, ureters, 
colon and pelvic muscle (Bell et al., 1991; Cornell et al., 2000). 
In cases of prostate cancer, abdominal and rectal palpation can showed a large, 
asymmetrical, irregular and painful prostate gland. Haemogram, serum biochemistry, 
urinalysis and urine culture, as the symptoms of prostate cancer can mimic those of a 
urinary tract infection or kidney disease. Neoplastic epithelial cells may be seen 
cytologically on evaluation of urine or prostatic fluid. Another common test is an 
ultrasound of the prostate gland. This is the preferred method for assessing the general 
health of the prostate, as it can help to distinguish between prostatic cysts, abscesses and 
tumors. A fine needle aspirate of cells from the prostate gland can be done with 
ultrasound guidance, which also can help distinguish between benign prostatic 
hypertrophy (BPH), prostatitis, abscesses and cancer. Thoracic (chest) and abdominal 
radiographs (X-rays), as well as abdominal ultrasound, can be useful to look for signs of 
metastasis. Regional lymph nodes can be sampled by fine needle aspiration, or removed 
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entirely, and examined microscopically for the same purpose. Biopsy of the prostate, 
with subsequent microscopic (histopathologic) evaluation of the tissue samples, is the 
only definitive way to diagnose prostate cancer.  Biopsy of the prostate will enable the 
veterinary pathologist not only to diagnose the existence (or absence) of cancer, but also 
to identify what type of cancer, if any, is involved. The lack of markers for PC makes 
early diagnosis difficult. 
There is no known way to prevent PC because prostatic tumors are not influenced 
by testosterone, castration does not reduce the risk of this disease or slow its progression 
but it was proved that in castrated dogs the risk factor of developing PC is 2,38 fold 
higher than in intact ones (Teske et al., 2002).  
Surgical resection is the only viable “cure” for prostate cancer. However, since the 
cancer usually has metastasized by the time it is diagnosed, surgical rarely is a curative 
option and tratment with curative intent is rendered difficult by the fact that radical 
prostatectomy in dogs with prostatic disease is associated with a very high incidence of 
postoperative urinary incontinence (Basinger et al., 1987). 
 Radiation and chemotherapy can be used to help minimize the effects of prostate 
disease and to help affected dogs live as comfortably as possible for the duration of their 
lives (Bell et al., 1991).  
Dogs with naturally-occurring prostate cancer are relevant models for the disease in 
humans and pre-clinical studies of new diagnostics and therapies in dogs may benefit 
both humans and dogs with prostate cancer (Leroy and Northrup, 2009). 
 
Prostate cancer is the most commonly diagnosed cancer in men. It is estimated that 
1 in 6 men will be diagnosed with prostate cancer within their lifetime and 1 in 36 will 
die from the disease. Prostate cancer is also the second leading cause of all cancer 
related deaths in men. The five year survival rate for men diagnosed with local or 
regional prostate cancer is 100%. However, men diagnosed with a distant metastasis 
have a five year survival rate of just 29%. Most men who die of prostate cancer present 
with hormone refractory prostate cancer (HRPC) (Siegel et al., 2012). Androgen 
deprivation therapy (ADT) is the predominant form of treatment for men diagnosed with 
regional prostate cancer. ADT suppresses testicular androgen synthesis and inhibits 
androgen receptor activation. However, most patients acquire resistance to ADT and 
develop hormone refractory prostate cancer (HRPC) following therapy (Messing et al., 
1999). This more advanced form of prostate cancer that is hormone refractory does not 
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rely on the presence of androgens for growth (Saraon et al., 2011). To significantly 
improve survival in men with PC, new therapeutic strategies to inhibit the appearance of 
this phenotype must be developed. PI3K/Akt/mTOR pathway plays a central role in 
various cellular processes including protein synthesis, cell cycle, cell survival, cell 
growth, motility and angiogenesis (Markman et al., 2010) and contributes to prostate 
cancer progression and transition to androgen-independent disease. Recent studies also 
demonstrated that this pathway is often deregulated during prostate cancer progression. 
Thus, targeting PTEN/PI3K/Akt and mTOR signaling pathway could be an effective 
strategy for the treatment of hormone refractory CP (Burgio et al. 2012). Many small 
molecule inhibitors targeting PI3K, Akt and/or mTOR are currently at various stages of 
clinical development. Despite promising results in certain preclinical tumor models 
(Markman et al., 2010), clinical responses to small molecule inhibitors of this pathway 
have been limited, since PI3K, Akt or mTOR inhibition typically promotes growth arrest 
rather than cell death in solid tumors (Cheng et al., 2009).  
 
PROSTATE CANCER AND TCDD 
 
In vivo studies, in mice and rats, demonstrated that TCDD exposure, early in 
development, can cause abnormal prostate development and may increase susceptibility 
to prostate cancer (Theobald and Peterson, 1997).  
In fact, a single maternal dose (GD: gestation day  13) inhibits prostate growth, 
reducing  ventral, dorsolateral, and anterior prostate weight , inhibits and delays 
differentiation of prostatic luminal epithelial cells and pericordial smooth muscle cells 
(Roman et al., 1998) decreases the number of main ducts and inhibits branching 
morphogenesis of all prostate lobes in rats, inhibiting the ductal morphogenesis and 
branching (Roman et al., 1998; Timms et al., 2002). 
The effects of TCDD on prostate development in mice has focused on the ontogeny 
of these abnormalities, in large part because prostatic vulnerability to TCDD starts 
before birth (Lin et al., 2002). Morphologically, prostate development begins when 
urogenital sinus (UGS) epithelium begins to develop buds in response to inductive 
signals from the surrounding mesenchyme. It is demostrated that maternal TCDD 
treatment delays the formation of anterior and dorsolateral prostatic epithelial buds in 
mice by about a day, reduces the number of dorsolateral buds by about 25%, and 
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prevents ventral buds from forming  (Lin et al., 2003). Effects on prostatic budding can 
account for many of the prostatic effects of TCDD seen in adult mice. 
 It is well known that perturbations of early development can have lifelong 
consequences for the prostate and that most prostatic diseases occur later in life depend 
from this perturbation (Schulman, 2000). 
More importantly, in aged rats, exposed to TCDD, greater epithelial proliferation 
was accompanied by morphological alterations manifested as lobe-specific hyperplasia. 
The cribriform structures it was observed in the mouse are closely reminiscent of lobe-
specific hyperplasia observed in the aging rat.  Cribriform structures are commonly seen 
in the early stages of benign prostatic hyperplasia, and have also been reported in aged 
rats that develop spontaneous prostate adenocarcinoma and in transgenic mice that 
develop prostate cancer. While the presence of cribriform structures does not necessarily 
mean that overt prostatic disease will develop, some investigators consider these 
structures in rodents to be precancerous lesions (Fritz et al., 2005).  
Descriptive studies on cancer mortality and congenital anomalies confirmed the 
presence of marked excesses of prostate cancer mostly in the same areas where dioxin 
levels were elevated  (Goldberg et al., 1995). 
Different studies evaluated the relation between Agent Orange exposure and 
prostate cancer in Vietnam veterans yielded conflicting results and were limited by small 
sample sizes and the lack of quantification of Agent Orange exposure (Zafar and Terris, 
2001; Giri et al., 2004; Everly et al., 2009). 
Furthermore, it was demonstrated in vitro that TCDD induces cytochrome P450 
(CYP) 1A1 and CYP1B1 via the aryl hydrocarbon receptor (AhR) in PC3 and DU145 
hormone-independent human prostate cancer cell lines. The induction of CYP1A1 and 
CYP1B1 by TCCD in hormone-independent prostate cancer cell lines suggests that CYP 
induction should be considered in patients with advanced prostate cancer. This effect of 
TCDD could result in higher elimination rates of concomitant drugs metabolized by 
these particular CYP isoenzymes (Schaufler et al., 2002).  
 
AUTOPHAGY  
Autophagy is a tightly regulated process playing a normal part in cell growth, 
development, and homeostasis and helping to maintain a balance between the synthesis, 
degradation, and subsequent recycling of cellular products through the degradation via 
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the lysosome. The initiation of autophagy begins with the formation of the 
autophagosome, which consists of cytoplasmic material sequestered inside a double 
membrane vescicle. Then, the autophagosome fuses with the lysosome and the 
cytoplasmic material is digested by hydrolases (Demarchi et al., 2006).  
 
Figure 7: Autophagy (Klionsky et al. 2012). 
 
Defects in this system are linked with pathogenesis of numerous diseases, including 
neurodegenerative disease (Rubinsztein et al., 2007), liver disease (Perlmutter, 2006), 
muscle disease (Nishino, 2006), cardiac disease (Terman and Brunk, 2005) microbial 
infection and cancer (White and DiPaola, 2009). The abnormal expression of Beclin-1 
and LC3 has been found in human melanoma (Pirtoli et al., 2009), colon (Li et al., 
2009), ovarian (Shen et al., 2008) and brain cancer (Miracco et al., 2007). 
The autophagic pathway can be stimulated by multiple forms of cellular stress, 
including nutrient or growth factor deprivation, hypoxia, reactive oxygen species, DNA 
damage, protein aggregates, damaged organelles, or intracellular pathogens (Kroemer et 
al., 2010). Autophagy stress-induced most often exerts cytoprotective functions and 
favors the re-establishment of homeostasis and survival (Chen and Karantza, 2011). 
Autophagy is regulated by a cellular network that involves upstream signaling 
pathways and this network is composed of 751 interactions with extensive connectivity 
among sub-networks: ULK kinase, PlKC3-BECN1, ATG2-WIPI, UBL conjuction 
system, human ATG8’s and AMP kinase (Fig. 8A) (Behrends et al., 2010).  
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Fig 8A: Autophagy interactive network. Modifed by Behrends et al., 2010. 
 
 
Figure 8B: Autophagy (From http://www.cellsignal.com/reference/pathway/Autophagy.html). 
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Class III PI3K complex, containing hVps34, Beclin 1, p150 (a mammalian homolog 
of yeast Vps15), and Atg14-like protein,  is required for the induction of autophagy. The 
formation of autophagosomes is initiated by class III phophoinositide 3-kinase and 
Beclin-1, this complex play a key role in mammalian autophagy (Eskelinen and Saftig, 
2009). Then, autophagosomes fuse with the lysosome, forming autophagolysosomes 
promoting the intracellular degradation. LC3-I  (microtubule-associated protein chain 3 
protein) is processed and activated by an ubiquitination-like reaction regulated by Atg7 
and Atg3. The abundant cytoplasmic LC3-I recruited during the formation of 
autophagosomes, is cleaved into a soluble form known as LC3-II, special marker of 
autophagy (Tanida et al., 2004).  
       Nutrient and/or growth factor availability activates the PI3K/AKT/mTOR axis, 
which inhibits autophagy thus stimulating cell growth and proliferation (Li et al., 2009; 
Pirtoli et al., 2009; White and DiPaola, 2009). 
The kinase mTOR is a regulator of autophagy induction, negative regulation of 
mTOR  promoting it. Three related serine/threonine kinases, UNC-51-like kinase -1, -2, 
and -3 (ULK1, ULK2, UKL3),  act downstream of the mTOR complex. ULK1 and ULK2 
form a large complex with the mammalian homolog of an autophagy-related (Atg) gene 
product (mAtg13) and the scaffold protein FIP200 (an ortholog of yeast Atg17).  
The Atg genes control the autophagosome formation through Atg12-Atg5 and LC3-II 
(Atg8-II) complexes. Atg12 is conjugated to Atg5 in a ubiquitin-like reaction that 
requires Atg7 and Atg10 (E1 and E2-like enzymes, respectively). The Atg12–Atg5 
conjugate then interacts noncovalently with Atg16 to form a large complex. LC3/Atg8 is 
cleaved at its C terminus by Atg4 protease to generate the cytosolic LC3-I. LC3-I is 
conjugated to phosphatidylethanolamine (PE) also in a ubiquitin-like reaction that 
requires Atg7 and Atg3 (E1 and E2-like enzymes, respectively). 
 Autophagy and apoptosis are connected both positively and negatively, and extensive 
crosstalk exists between the two. During nutrient deficiency, autophagy functions as a 
pro-survival mechanism; however, excessive autophagy may lead to cell death, a process 
morphologically distinct from apoptosis (Tanida et al., 2001). 
. 
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AUTOPHAGY AND CANCER  
The role of autophagy in cancer is controversial, as the factors that determine 
whether autophagy induces tumor cell death or protects tumor cells from unfavorable 
conditions have not been clearly elucidated (Rosenfeldt and Ryan, 2011). Autophagy is 
reported to play an anti-tumoral role by reducing the chromosomic instability, thus 
avoiding DNA damage (Mathew et al., 2007) and  inhibiting cell proliferation (Levine 
and Klionsky, 2004; Pua et al., 2007).  On the other hand, several studies demonstrated 
that autophagy-mediated support of tumor cell survival may play a critical role in cancer 
progression at later stages, such as dissemination and metastasis, which account for most 
cancer-associated deaths. Autophagy acts as an anti-apoptotic mechanism for tumor 
cells under stress, maintaining metabolism and energy needed for survival (Mathew et 
al., 2007) and could promote angiogenesis and tumor progression (Degenhardt et al., 
2006; Mathew et al., 2007). 
In favor of this hypothesis, starvation-induced autophagy is accompanied by 
suppression of protein synthesis, cell division and motility in an energy conservation 
effort that sustains cells in a dormant state with the capacity to resume cell growth and 
proliferation upon regular growth condition restoration. For example, autophagy 
induction in mammary epithelial cells upon their detachment from extraceullular matrix 
(ECM) sustains cell viability in an anoikis-resistant manner, whereas autophagy 
upregulation in ovarian cancer cells by the tumor suppressor ARHI (aplasia Ras 
homolog member I) promotes dormant cell survival in vivo (Chen and Karantza, 2011). 
 It was demostrated in some prostate cancer cell lines (LNCaP and PC346-Flu1) are 
very sensitive to monotherapy with the AKT inhibitor AZD5363, where the compound 
induces significant apoptosis at concentrations achievable in preclinical models, other 
prostate cancer cell lines, such as DU-145 and PC3, are relatively resistant. In fact, it 
was reported that AZD5363 monotherapy induced growth arrest and autophagy and  
failed to induce significant apoptosis in PC-3 and DU145 PCa cells. In light of these 
reasons, autophagy seems to be a good candidate for prostate cancer research because its 
deregulation in this disease (Lamoureux et al., 2013). Finally, many studies have clearly 
documented that in cancer cells, autophagy is upregulated in response to metabolic and 
genotoxic stress induced by hormonal deprivation, chemotherapy and radiation as a cell 
survival mechanism, likely contributing to treatment resistance (Chen and Karantza, 
2011). 
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Furthermore, autophagy became a novel therapeutic target in cancer because 
inhibition or induction of autophagy promotes cancer cell death and potentiates various 
anticancer therapies (White and DiPaola, 2009). The impact of autophagy inhibition on 
anticancer therapy has been evaluated in multiple tumor models, including glioma (Ito et 
al., 2005), myeloma (Shanmugam et al., 2009), breast (Vazquez-Martin et al., 2009), 
colon (Apel et al., 2008), and prostate cancers (Kim et al., 2009). 
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TCDD represents a persistent organic pollutant and exposure to TCDD can result in 
a number of toxic effects in several species (Pohjanvirta and Tuomisto, 1994). In 1997, 
the International Agency for Research on Cancer (IARC) classified TCDD as 
carcinogen (IARC, 1997) but the molecular mechanisms of action of TCDD have not 
been elucidated so far (Mandal, 2005).  
Prostate cancer (PC) is an extremely serious disease in dogs (LeRoy and Northrup, 
2009) and PC represents the most commonly diagnosed cancer in males in the Western 
world (Siegel et al., 2012). In general, animal models of human cancer have evolved in 
attempts to capture the complexity of the human disease because the canine prostate 
gland shares many morphological and functional similarities with the human prostate 
(LeRoy and Northrup, 2009). Consequently, to evaluate the biological effects of TCDD 
on prostate cancer in this study we used human prostate cancer cell line, PC3. Until now, 
very few data are present in literature about PC3 and TCDD exposure. It is known that 
in PC3 cell line, a hormone-independent prostate cancer cell line, TCDD induces 
CYP1A1 and CYP1B1 via AhR. This effect of TCDD could result in higher elimination 
rates of concomitant drugs metabolized by these particular CYP isoenzymes (Schaufler 
et al., 2002). Moreover, several studies suggest that TCDD exposure is associated with 
abnormal prostate development, altered prostate pathology and increase susceptibility to 
prostate cancer (Theobald and Peterson, 1997; Fritz et al., 2005; Everly et al., 2009) and 
cancer mortality descriptive studies demonstrated an increase of incidents rates of the 
prostate cancer in the same areas where dioxin levels were elevated (Goldberg et al., 
1995).  
The administration of TCDD to a variety of cultured cells may alter their ability to 
proliferate and die. In a previous study we demonstrated that TCDD induced 
proliferation in Madin-Darby Bovine Kidney (MDBK), an epithelial cell line, in which 
analysis of MDBK cell morphology revealed some alterations in a large number of 
exposed cells, where neither signs of apoptosis nor necrosis were detected, but we found 
that TCDD activated cell death with autophagy (Fiorito et al., 2011).  
 Autophagy is a tightly regulated process playing a normal part in cell growth, 
development, and homeostasis and helping to maintain a balance between the synthesis, 
degradation, and subsequent recycling of cellular products through the degradation via 
the lysosome (Demarchi et al., 2006). Defects of autophagy machinery are responsible for 
pathogenesis of different diseases, including cancer. The role of autophagy in cancer is 
controversial. There is evidence that autophagy may play a critical role in cancer 
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progression at later stages, such as dissemination and metastasis, which account for most 
cancer-associated deaths, whereas in other cases it clearly contributes to tumor 
suppression by inducing tumor cell death (Chen and Karantza, 2011).  
Taking in account all the above, the aim of this study was to evaluate the biological 
effects of TCDD exposure to a highly metastatic prostate cancer cell line, PC3.       
      Indeed, a better understanding of inter-species mechanism of action of TCDD action 
is necessary to enhance the knowledge of TCDD role on prostate cancer that is the most 
commonly diagnosed cancer in males in the Western world and is an extremely serious 
disease in our dogs.  
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Cell culture  
 
Prostate carcinoma cells PC3 were purchased from ATCC (American Type Culture 
Collection, Manassaa, Va, USA). Cells were grown to 70–80% confluence in ATCC-
formulated F-12K Medium (Catalog No. 30-2004), containing 10% fetal bovine serum 
(Invitrogen, Carlsbad, CA) in a 37°C humidified incubator supplied with 5% of carbon 
dioxide (CO2) 
 
TCDD 
 
TCDD (Supelco, 48599) was diluited at 0.01, 1 and 100 pg/ml in F-12K cell culture 
medium according to Fiorito et al. 2008a,b, 2010, 2011 and Santamaria et al. (2011). 
 
Cell Proliferation and Viability   
 
Cell proliferation and viability was assessed by Trypan blue (TB) exclusion test. PC3 
cells (5×10
4
 cells/well) were grown in 24-well plates, at 70–80% confluence, exposed to 
TCDD (0.01, 1, or 100 pg/ml) and incubated for 24, 48 and 72 h. Cells were collected by 
trypsinization, at the indicated times after TCDD exposure, and an aliquot of the cell 
suspension was mixed with an equal volume of 0.2% Trypan-blue (Sigma) in 1 × 
phosphate-buffered saline (PBS). After 10 min, the cells were evaluated in a Burker 
chamber at a light microscope. Stained blue cells with damaged cell membrane 
represented non-viable cells. Cell proliferation was evaluated by count of total number of 
cells. Cell viability was calculated as percentage of live cells over the total cells number, 
and results are the mean ± S.E.M. of four independent experiments performed in 
duplicate.  
 
Cell cycle analysis  
 
PC3 cells (1×10
5
 cells/ml), were grown in tissue culture dishes and exposed at 
different concentrations of TCDD (0.01, 1 or 100 pg/ml). After 24, 48 and 72 h of 
exposure, adherent cells were washed twice with PBS and removed from the dish by 
treatment with trypsin–EDTA solution. Then, 1 × 106 PC3 cells were harvested and fixed 
in 70% ethanol after washes with cold phosphate-buffered saline (PBS), and stored at 4°C 
until the analysis. After centrifugation, the resulting cell pellet was incubated in the dark 
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for 30 min, in 0.3 ml of freshly prepared PBS containing 0.02 mg/ml propidium iodide 
(PI) and 0.25 mg/ml ribonuclease A (Sigma). The samples were then analyzed for DNA 
content using a BD Accuri™ C6 Flow Cytometer (30,000 events/sample). 
 
Cell morphology analysis 
 
Cell morphology was performed by phase-contrast microscopy. PC3 cells (5×10
4
 
cells/well) were grown in 24-well plates, at 70–80% confluence, exposed to TCDD (0.01, 
1, or 100 pg/ml) and incubated for 24, 48 and 72 h. Cells were washed twice with PBS, 
fixed with 95% ethanol, drained and dried. The slides were mounted in Entellan (Merck, 
100869), coverslipped and phase-contrast microscopy studies and photomicrographs 
observations were carried out. 
 
Acridine orange staining  
 
The staining with acridine orange was performed to detect AVOs. PC3 cells (5×10
4
 
cells/well) were grown in 24-well plates, at 70–80% confluence, exposed to TCDD (100 
pg/ml) or, autophagy inductor, thapsigargin (TG) (0.5 µM) (Grotemeier et al., 2010) and 
incubated for 48 h. After exposure to TCDD or TG, cells were washed with PBS and 
stained with acridine orange (Sigma, A6014) at a final concentration of 1 µg/ml for 15 
min. Stained cells were placed on a microscope slide and observed under UV with a 
fluorescence microscope (Olympus). 
 
Immunofluorescence microscope analysis 
PC3 cells (1×10
4
 cells/well) were grown in chambers slide, exposed to TCDD (100 
pg/ml) or TG (0.5 µM) and incubated for 48 h. Cells were washed with PBS and then 
fixed with paraformaldehyde (4%, w:v). After rinsing in PBS, the cells were 
permeabilized with 0.1% Triton X-100 in PBS for 1 min and blocked in 4% BSA in PBS 
for 30 min. This was followed by incubation in rabbit polyclonal microtubule associated 
protein light chain 3A/B (LC3A/B) antibody (1:50) (ABCAM, ab58610), for 24 h at 4°C 
in a humidified chamber. Cells were washed with PBS and then incubated in Goat Anti-
Rabbit IgG (1:1000) (Alexa Fluor® 594) for 1 h at room temperature. Finally, cells were 
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rinsed in PBS, coverslipped and observed under UV with a fluorescence microscope 
(Nikon). 
 
Gene expression analysis 
 
PC3 cells were grown in tissue culture dishes and exposed to TCDD (100 pg/ml), 
autophagy inhibitor chloroquine (CQ, 10µM) and TG (0.5 µM) in the following: PC3 
exposed to TCDD (PC3_TCDD); PC3 exposed to TCDD and CQ (PC3_TCDD+CQ); 
PC3 exposed to TG (PC3_TG). After 24, 48 and 72 h of exposure, PC3_TCDD, 
PC3_TCDD+CQ and PC3_TG cells were collected and total RNA extraction was 
performed using RNeasy Mini Kit (Qiagen, Catalog no. 74104) according to the 
manufacturer’s instruction. Reverse transcription of 1 μg of total RNA as a template was 
used to produce cDNA using High Capacity cDNA Reverse Transcription kit (Applied 
Biosystem) according to the manufacturer’s instructions. Real-time PCR was performed 
using the LightCycler® 480 Real-Time PCR System (Roche Applied Science) in 
reactions of 25 µl containing 100 ng of cDNA, 10 µl of TaqMan® Universal PCR Master 
Mix (2x), No AmpErase®, UNG (Applied Biosystems®, Catalog Number: 4366072), 
and 1 µl  of TaqMan® Gene Expression Assay (20x)(Applied Biosystem). The target 
gene analyzed was LC3 (LC3, Hs00917683) and the reference used was hypoxanthine-
guanine phosphoribosyltransferase (HPRT, 4333768)  
 
Protein extraction and Western blot analysis 
 
PC3 cells were grown in tissue culture dishes and exposed to TCDD (100 pg/ml) and 
autophagy inhibitor chloroquine (CQ, 10µM). After 48 h of exposure adherent cells were 
washed twice with PBS and removed from the flask by treatment with trypsin–EDTA 
solution. Then cells were collected by centrifugation and resuspended at an adequate 
concentration in PBS. The pellets, obtained by centrifugation, were stored at -20° C. 
Later it, cells were homogenized into lysis buffer (50 mM HEPES, 150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 1 mM phenylmethylsulfonyl 
fluoride, 1 µg/ml aprotinin, 0.5 mM sodium orthovanadate, and 20 mM sodium 
pyrophosphate).  
The lysates were clarified by centrifugation at 14,000 rpm × 10 min. Protein 
concentrations were estimated by an assay (Bio-Rad) and boiled in Laemmli buffer 
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[0.125 M Tris–HCl (pH 6.8), 4% SDS, 20% glycerol, 10% 2- mercaptoethanol, and 
0.002% bromophenol blue] for 5 min before electrophoresis.  
Proteins were subjected to SDS-PAGE (12.5% polyacrylamide). After 
electrophoresis, proteins were transferred to nitrocellulose membranes (Millipore, 
Immobilon); complete transfer was assessed using pre-stained protein standards (Bio-
Rad). After blocking with Tris–buffered saline–BSA [25 mM Tris (pH 7.4), 200 mM 
NaCl, and 5% BSA], the membrane was incubated with the primary antibodies. The 
following antibodies, dissolved in 5% bovine serum albumin-TBST, were used: rabbit 
polyclonal microtubule-associated protein light chain 3A/B (LC3A/B) antibody (1:800) 
(ABCAM, ab58610), for 24 h at 4° C in a humidified chamber. After membranes were 
then incubated with the horseradish peroxidase-conjugated secondary antibody (1:1000) 
(at room temperature), and the reaction was detected with an enhanced 
chemiluminescence system (Amersham Life Science). The images of Western 
immunoblot specific bands on X-ray films were imported into a computer by a scanner 
and captured as digital TIFF images. The results were plotted in a graph after 
densitometry analysis of the blots obtained. 
 
Autophagy Related Gene Expression Profiling 
 
The analysis of the autophagy pathway was performed using RT
2
 Profiler™ PCR 
Array (Quiagen, PAHS-084ZF).  
PC3 cells were cultered in tissue culture dishes and exposed to TCDD (100 pg/ml) or 
to TG (0.5 µM).  After 48 h of exposure, PC3 cells were collected and total RNA 
extraction was performed using RNeasy Mini Kit (Qiagen, Catalog no. 74104) according 
to the manufacturer’s instruction. Reverse transcription of 2 μg of total RNA was 
performed to produce cDNA using RT
2
 First strand kit (Quiagen 330401) according to 
the manufacturer’s instructions.  
RT
2
 Profiler™ PCR Array profiles the expression of 84 genes involved in 
autophagy. Controls for genomic DNA contamination and for the efficiency of the RT-
PCR and PCR reactions were also included in the array. Each cDNA samples was mixed 
with RT
2 
SYBR Green qPCR Master Mix (330500) and then added to the 96-well plate. 
The PCR was performed in LightCycler® 480 Real-Time PCR System (Roche Applied 
Science) and the results were calculated using the comparative CT method for separate 
tubes with GAPDH and RPLP0 as housekeeping genes. The fold change of gene 
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expression was calculated using the Excel-based PCR Array data analysis program 
(Qiagen). 
 
DATA ANALYSIS 
 
Data are presented as mean ± S.E.M. One-way ANOVA with Tukey’s post-test was 
performed using GraphPad InStat Version 3.00 for Windows (GraphPad Software, San 
Diego, CA). A p value <0.05 was considered statistically significant. 
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TCDD enhances PC3 cell proliferation and viability  
We analyzed the effect of TCDD exposure on PC3 cell proliferation and viability by 
Trypan blue (TB) exclusion test. PC3 cells were incubated in the presence of 0.01, 1 and 
100 pg/ml of TCDD and then the TB exclusion test was performed at different times of 
exposure, 24, 48 and 72h. As shown in Fig. 9A, the exposure of various doses of TCDD 
on PC3 cells caused a significant increase in the total cells number of cells at all 
concentrations of TCDD studied from 24 to 72 h of exposure (p < 0.001 and p < 0.05). 
TCDD exposure determined an increase in cells proliferation (Fig. 9), in dose-dependent 
manner at 24 and 48 h.  Whereas, examining treated cells at 0.01 and 100 pg/ml of TCDD 
compared to 1 pg/ml of TCDD at 72 h, we observerd an U-shaped does responsiveness 
cell proliferation (see also Discussion).  
As shown in Fig. 9B, the exposure of various doses of TCDD on PC3 cells caused a 
significant increase in the cell viability in dose-dependent manner at all concentrations of 
TCDD studied from 24 to 72 h of exposure (p < 0.001, p < 0.01 and p < 0.05).  
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Fig.9: Effects of exposure to different concentrations of TCDD (0.01, 1, or 100 pg/ml) and incubated 
for 24, 48 and 72 h on PC3 cell proliferation (A) and viability (B). Data are presented as a percentage of the 
control (B) and results are expressed as the mean ± SE of four independent experiments performed in 
duplicate (A and B). Significant differences between unexposed groups and TCDD-exposed groups are 
indicated by probability p. *p < 0.05, **p < 0.01 and ***p < 0.001.  
 
Moreover, Trypan-blue exclusion test also indicated that no significant differences 
were observed between control and TCDD-treated groups in time dependent alteration of 
cell membrane permeability (TB permeable cells), at all tested doses tested (Fig.10).  
TCDD does not induce cell death in PC3 but TCDD enhances PC3 cells viability and 
proliferation. 
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Fig. 10. Effects of exposure of different concentrations of TCDD (0.01, 1, or 100 pg/ml) incubated for 
24, 48 and 72 h on cell membrane permeability/cell death. Values were percentage of non-viable cells, as 
determined by assessment of cells permeable to Trypan-blue. Data are presented as percentage of TB 
permeable cells. Data are presented as a percentage of the control and results are expressed as the mean ± 
S.D. of four independent experiments performed in duplicate. 
 
 
   
TCDD induces cell cycle progression 
 
TCDD significantly increased the cell population at S phase at 24 with 1 and 100 
pg/ml and at 48h with 0.01 pg/ml compared with contol (Fig. 11). So, TCDD induces cell 
cycle progression. 
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Fig.11: Effects of TCDD exposure to PC3 cell proliferation.  PC3 cells exposed to different 
concentrations of TCDD (0.01, 1, or 100 pg/ml) were collected at 24, 48 and 72 h and the cell cycle 
analysis was performed by flow cytometry. Results of flow cytometry are shown as cell cycle analys (Fig. 
3A) and as representative histograms of cell cycle distribution (Fig. 3B). Results are representative of 3 
independent experiments.  
 
 
TCDD induces morphological alterations in PC3 cells 
PC3 cells were incubated in the presence of 0.01, 1 and 100 pg/ml of TCDD and cell 
morphology analysis was performed at different times of TCDD exposure, 24, 48 and 
72h, by phase-contrast microscopy. At 48 h, a large number of cells showed the following 
morphological charateristic signs of autophagy: expanded cytoplasm (magnified cells) 
and an elevated degree of vacuolization, suggesting autophagy (Fig. 12). As positive 
control, we used TG (0.5 μmol/L), an inductor of autophagy. Cells exposed to TG 
showed an elevated degree of vacuolization similar to TCDD (Fig 12).  
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Fig 12. Effects of different concentrations of TCDD (A, B, C) or TG (D) exposure on PC3 cell 
morphology. PC3 cells were treated with different concentrations of TCDD (0.01, 1 and 100 pg/ml) or with 
TG (0.5 μmol/L) and then observed under light microscope. After 48 h of exposure, TCDD exposed PC3 
cells compared to the control groups, displayed significant vacuole formation (A, magnification 10X; B, 
magnification 20X; C magnification 40X). After 48 h of exposure, TG exposed cells compared to the 
control group, displayed a similar elevated degree of vacuolization (D, magnification 10X, 20X and 40X). 
 
TCDD induces AVOs formation in PC3 cells 
 
The effects of TCDD treatment on PC-3 cells were evaluated by fluorescence 
microscopy following staining with the lysosomotropic agent acridine orange (Fig. 13). 
In acridinge orange-stained autophagic cells, the cytoplasm and nucleolus fluorescence 
bright green and dim red, whereas acidic compartments fluorescence bright red (Traganos 
and Darzynkiewicz, 1994; Chiu et al., 2009). The intensity of the red fluorescence is 
proportional to the degree of acidity of the cellular acidic compartment. Untreated PC-3 
cells displayed primarily green fluorescence with minimal red fluorescence (minimal 
presence of AVOs) while PC-3 cells treated with TCDD (100 pg/mL) displayed red 
fluorescence (increased presence of AVOs) (Fig. 13A). The presence of AVOs and 
expanded cytoplasm (magnified cells), represent characteristic signs of autophagy 
(Kroemer and Levine, 2008; Zakeri et al., 2008; Lamparska-Przybysz et al., 2005). 
Similar morphological alterations were displayed in PC3 exposed to the autophagy 
inductor TG (Fig. 13B).  
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Fig. 13. Morphological effects of TCDD (A) or TG exposure (B) on PC3 by acridine orange staining. 
PC3 cells were treated with TCDD or with TG, stained with acridine orange and then observed under light 
microscope. After 48 h of exposure, untreated PC-3 cells displayed minimal presence of AVOs (green 
fluorescence with minimal red fluorescence), while PC3 cells treated with TCDD (100 pg/mL) displayed 
increased presence of AVOs (red fluorescence) (A, magnification 10X; 20X; 40X).  Similar morphological 
alterations were displayed in PC3 exposed to TG (0.5 μmol/L) (B, magnification 10X; 20X; 40X).  
 
TCDD induces alteration of LC3 expression in PC3 cells 
 
The effects of TCDD (100 pg/ml), TCDD (100 pg/ml) and CQ (10µM) or TG (0.5 
μmol/L) on relative mRNA levels of the autophagic marker LC3 (Kabeya et al., 2000; 
Wu et al., 2006), were evaluated in PC3 cells at 24, 48 and 72 h by Real Time PCR. 
TCDD induced a significant increase of mRNA levels of LC3 at 48 and 72 h (p < 0.001), 
indicating a high rate of autophagy for PC3 cells exposed to TCDD. In details, PC3 cells 
showed the following LC3 expression ratios: 1.4 (after 24 h), 6.2 (after 48 h) and 11.4 
(after 72 h). Treatment of PC3 cells with TCDD in absence or presence of CQ was used 
to assess the autophagic flux. Fig 14A shows a significant downregulation of LC3 mRNA 
levels (p < 0.001) after exposure to TCDD and CQ with the following expression ratios: -
12.8 (after 24 h), -28.1 (after 48 h), and -2.8 (after 72 h). As positive control, we use the 
autophagy inductor TG. TG induced a significant increase of LC3 mRNA levels at 48h 
(expression ratio= 11.7, p < 0.001) (Fig. 14A).  
Furthermore, to assess the autophagic flux, we used the western blot analysis of LC3 
protein in PC3 cells exposed to TCDD in absence or presence of CQ. Fig. 14B  shows 
that CQ increased LC3-II accumulation in presence of TCDD at 48 h post exposure, 
when significant TCDD-induced autophagy started (Fig. 14A). These results confirmed 
that TCDD activated autophagic flux, indeed autophagy can increase as a compensatory 
means of protein degradation when the autophagic pathway is blocked (Pandey et al., 
2007). (Fig. 14B). 
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Fig. 14 TCDD exposure induces alteration of LC3 gene expression (A) and activated autophagic flux 
increased the levels of LC3-II protein (B and C). Expression of relative mRNA levels of LC3 in PC3 cells 
exposed to TCDD (100 pg/ml), or TCDD and CQ (10µM) or TG (0.5 μmol/L) at 24, 48 and 72 h  by Real 
time PCR (A). TCDD exposure induces alteration of levels of LC3 protein at 48h  of exposure. Western 
blot analysis was performed with an antibody which specifically recognized LC3, Actin was used as an 
internal loading control (B) and representative histograms of relative density of LC3-II (C). 
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Since, we analyzed the effects of TCDD (100 pg/ml), or TG (0.5 μmol/L) exposure  
on LC3 protein expression, after 48 h, by immunofluorescence. Immunofluorescence is 
considered reliable methods for monitoring autophagy (Tanida et al., 2008). Both TCDD 
and TG singles treatments showed an increased LC3 punctate staining when compared to 
its controls (Fig. 15A/B). 
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Fig. 15. LC3 detection of TCDD (A) or TG (B) exposure on Pc3 cells by immunofluorescence. 
TCDD (100 pg/ml), or TG (0.5 μmol/L) exposure on levels of LC3 showed an increased LC3 punctate 
staining when compared to its controls after 48 h of treatment confirming that TCDD exposure induced 
autophagy in PC3 cells. (A, magnification 10X; 20X; 40X). Similar morphological alterations were 
displayed in PC3 exposed to TG (0.5 μmol/L) (B, magnification 10X; 20X; 40X).  
 
 
 
TCDD modulates Autophagy related Transcriptomics  
 
In order to analyze the effects of TCDD exposure on PC3 cells at transcriptional 
levels, we evaluated the gene expression profiles of some genes involved in the following 
pathways: autophagic vacuole formation; protein targeting to membrane/vacuole; protein 
transport autolysosome formation; protein ubiquination; protease activity; co-regulation 
of autophagy and apoptosis; and cell cycle. The gene expression profiles of PC3 cells 
after 48h of TCDD or TG exposures are shown the results illustrated in Fig 16 and Tab 
1.   
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Fig. 16. Gene expression profile analysis of PC3 cells exposed toTCDD (A). Gene expression profile 
analysis of PC3 cells exposed to TG (B). mRNA levels of genes involved in autophagy were analyzed by 
quantitative RT-CR. Left: scatter plot data analysis. mRNA levels of genes involved in autophagy were 
analyzed by quantitative RT-PCR. Right: positive and negative regulations of gene expression. It was used 
a cut-off ratio ≥2.  
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Table 1. Modulation of gene expression by TCDD and TG exposure with a cut-off ratio ≥2. Red: 
positive modulation; blue: negative modulation. mRNA levels of genes involved in autophagy were 
analyzed by quantitative RT-PCR.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Symbol Modulation by TCDD Modulation by TG 
AKT1 -3.17 -2.21 
ATG10 2.54 2.31 
ATG4C 2.4 2.23 
ATG5 2.18 2.08 
BECN1 2.5228 1.99 
GABARAPL1 2.69 3.8 
MAP1LC3B 3.08 5.05 
MAPK8 2.4 2.17 
PRKAA1 2.18 1.98 
WIPI1 2.92 4.33 
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 Autophagy is a tightly regulated process playing a normal part in cell growth, 
development, and homeostasis and helping to maintain a balance between the synthesis, 
degradation, and subsequent recycling of cellular products through the degradation via 
the lysosome (Demarchi et al., 2006). Defects of autophagy machinery are responsible 
for pathogenesis of different diseases, including cancer. The role of autophagy in cancer 
is controversial. There is evidence that autophagy may play a critical role in cancer 
progression at later stages, such as dissemination and metastasis, which account for most 
cancer-associated deaths, whereas in other cases it clearly contributes to tumor 
suppression by inducing tumor cell death (Chen and Karantza). 
We have demonstrated that the exposure of TCDD enhances PC3 cell viability and 
proliferation (Fig. 9) and the alteration of differentiation and proliferation is associated 
with tumor promotion and TCDD-induced dysregulation of cellular growth and 
differentiation suggesting a possible involvement of TCDD in prostate cancer 
progression. 
These results took place in a dose-dependent manner at 24 and 48 h, in accordance 
with other studies on normal cells (Fiorito et al., 2008; Santamaria et al., 2011), as well as 
in cancer cells, as colon cancer cells (Xie et al., 2012) and breast cancer cells (Moore et 
al., 1993; Chen et al., 2012). After 72 h of exposure with 0.01 and 100 pg/ml of TCDD 
compared to 1 pg/ml of TCDD, PC3 showed an U-shaped dose responsiveness. This 
modulation was too in accordance with literature (Murayama et al., 2002; Ahn et al., 
2005; Fiorito et al., 2008; Fiorito et al., 2011). 
Then, we study cell cycle analysis of PC3 cells exposed to TCDD. Our data showed 
an increase of cell population at S phase in cell cycle. This result was in accordance with 
a study where TCDD enriched the cell population in G2/M phase in breast cancer cells 
(Chen et al., 2012) and TCDD-induced modulation of cell cycle and cell proliferation in 
hepatoma and WB-F344 cells (Proikas-Cezanne et al., 2007). In the present study we 
demonstrated for the first time that TCDD-promoted S enrichment and proliferation of 
prostate cancer cells. 
Herein, analysis of cell morphology, by phase-contrast microscopy, demonstrated 
that PC3 cells exposed to TCDD, compared to controls, displayed a large number of cells 
with expanded cytoplasm (magnified cells) and an elevated degree of vacuolization, 
characteristic signs of autophagy, as reported above. These results were in accordance 
with previously described in HT-29 colon cancer cells exposed to hyperthermia in 
combination with oxidative stress (Chen et al. 2008). Furthermore, we used, as positive 
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control, thapsigargin (TG), an inductor of autophagy. Cells exposed to TG, at  0.5 
μmol/L, showed an elevated degree of vacuolization similar to TCDD. Our result was 
confirmed by acridne orange, where PC3 cells exposed to TCDD showed formation of 
AVOs that were relatively more control. Formation of AVOs is another characteristic 
feature of cells engaged in autophagy after treatment with different stimuli, including 
radiation or ceramide (Paglin et al. 2001). Finally, our results confirmed AVOs detection, 
as we previously reported after TCDD exposure in MDBK cells (Fiorito et al. 2011).  
The induction of autophagy is accompanied by an increase in the mRNA levels of 
certain autophagy genes, such as Atg8/LC3 and assessing the levels of LC3 mRNA by 
qRT-PCR may provide correlative data relating to the induction of autophagy (Kabeya et 
al., 2000; Wu et al., 2006).  TCDD exposure on PC3 cells increased the relative mRNA 
levels of the autophagic marker LC3 and this up-regulation suggests that PC3 cells 
evidenced a high rate of autophagy. This result was confirmed by western blot and 
immunofluorescence for detection of LC3 protein, a reliable methods for monitoring 
autophagy (Tanida et al., 2008). 
Furthermore, to assess the autophagic flux, we used the western blot analysis of LC3 
protein in PC3 cells exposed to TCDD in absence or presence of CQ and our samples 
shows that CQ increased LC3-II accumulation in presence of TCDD at 48 h post 
exposure, when significant TCDD-induced autophagy started. These results confirmed 
that TCDD activated autophagic flux, indeed autophagy can increase as a compensatory 
means of protein degradation when the autophagic pathway is blocked (Pandey et al., 
2007).  
Our understanding of the global organization the autophagy system is still limited. 
Recently, it was revealed the autophagy interaction network in human cells undergoing 
conditions of ongoing basal autophagy (Behrends et al., 2010). This network is 
composed of 751 interactions with extensive connectivity among sub-networks (Fig. 
8A).  
Autophagy is constitutively active on a basal level. As a consequence, the constant 
turnover of cytoplasmic material maintains cellular homeostasis. Above this basal level, 
autophagy is further induced upon activation of the PIK3C3/BECN-1 complex, that 
generates phosphatidylinositol 3-phosphate (PI(3)P, the product of both the class II and 
III phosphoinositide 3-kinases (PI 3-kinases) activity on phosphatidylinositol (Maiuri et 
al., 2007). The generation of PI(3)P is considered to be required for canonical induction 
of autophagy. In fact, BECN1 (BECN1; coiled-coil, myosin-like BCL2-interacting 
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protein), that is also known as autophagy-related gene Atg6, binding partner PI3K, for the 
initiation of the formation of the autophagosome in autophagy (Maiuri et al., 2007).  
One of the cofactors interacting with BECN1 is AMBRA1 (activating molecule in 
Beclin1-regulated autophagy). This positive regulator of BECN1 is known to activate the 
lipid kinase PIK3C3 (Jaber et al., 2012). From our results, TCDD upregulates PlK3C3-
BECN1 network by modulating PIK3C3 (Class III PI3K, Vps34), BECN-1 and 
AMBRA1 (Fig 17). This upregulation was novel, indeed, until now, there is no literature 
information available about this mechanism induced by TCDD. 
Autophagy induction is followed by an increase in the mRNA levels of Atg8/LC3/ 
MAP1LC3 (microtubule-associated protein 1 light chain 3). LC3 synthesis starts with the 
production of an unprocessed form, proLC3 that is then converted into a proteolytically 
processed form lacking amino acids from the C terminus, LC3-I and ultimately modified 
into the PE-conjugated form, LC3-II. Atg8—PE/LC3-II/ MAP1LC3B is the only protein 
marker that is reliably associated with completed autophagosomes, but is also localized to 
phagophores, the precursors to autophagosomes (Huang et al., 2000). MAP1LC3B, is 
significativly upregulated by TCDD (Fig17 and Table 1). Autophay induction by TG 
exposure, confirmed the same upregulation (Fig17 and Table 1). These results are in 
agreement with our previous work (Fiorito et al. 2011) where we demonstrated that 
TCDD induced autophagy in MDBK cells, by increasing the amount of LC3-II protein. 
LC3 is a member of ATG8 family that is composed of 6 members: MAP1LC3A, 
MAP1LC3B, MAP1LC3C, GABA(A) receptor-associated protein (GABARAP), 
GABARAPL1, and GABARAPL2. GABARAPL1 is not only involved in autophagy, 
partially colocalizes with LC3 in intracellular vesicles and was associates with autophagic 
vesicles (Chakrama et al., 2010), but is also implicated in various mechanisms such as 
cell proliferation and tumor progression. Our results indicate a positive modulation of 
GABARAPL1 in PC3 cells exposed to TCDD or TG. 
It is well known that Atg genes control the autophagosome formation. LC3 is 
initially synthesized with a C-terminal and then is cleaved at its C terminus by Atg4 
protease to generate the cytosolic LC3-I. There are four Atg4 homologs in mammals, and 
they have different activities with regard to the LC3/Atg8 subfamiles of proteins. ATG4A 
is able to cleave the GABARAP subfamily, but has very limited activity toward the LC3 
subfamily whereas, ATG4B is active against most or all of these proteins and ATG4C 
and ATG4D isoforms have minimal activity for any of the Atg8 homologs (Klionsky, 
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2011). Here, both ATG4A and ATG4C were upregulated after TCDD exposure, while 
TG exposure upregulated only ATG4C (Fig. 17, Table 1). 
Other Atg genes controlling the autophagosome formation/maturation and cargo 
recruitment are also the genes involved in the ubiquitin-like protein (UBL) conjugation 
system (Fig 18) - composed of the Atg3,  Atg5, Atg7, Atg10, Atg12 and ATG16L1 
(Behrends et al., 2010). Also, Atg10 is essential for normal cell cycle progression and for 
responses to various stress conditions that perturb the cell cycle (Flanagan et al., 2013). 
Our results indicate a novel positive modulation of 5 genes involved in the UBL 
conjugation system: ATG4C, ATG5, ATG7, ATG10, ATG16L1. ATG4C, ATG5 and 
ATG10 were modulated in PC3 exposed to both TCDD and TG.  
PRKAA (Protein kinase, AMP-activated, alpha 1 catalytic subunit), also called 
AMPK, is generally antagonistic toward MTOR function. AMPK-mediated mTORC 
inhibition and autophagy stimulation, for example, occur during glucose starvation. 
Aminoacid starvation, on the other hand, can strongly induce autophagy even in cells 
completely lacking AMPK catalytic activity (Klionsky et al., 2012). Our results showed a 
significant upregulation of this gene in PC3 cells exposed to TCDD, while in cells exosed 
to TG the upregulation is not significant. 
Human WIPI-1 (WD-repeat protein interacting with phosphoinositides-1) 
specifically binds PI(3)P and localizes at autophagosomal membranes upon PI(3)P-
mediated induction of autophagy (Proikas-Cezanne et al., 2007). The exposure with 
TCDD or TG resulted in a positive  regulation of WIPI-1  in our in vitro system.  
PC3 cells exposed to TCDD also showed upregulation of two member of the MAP 
kinase family: MAPK14 (Mitogen-activated protein kinase 14) and MAPK8 (Mitogen-
activated protein kinase 8). MAP kinases act as an integration point for multiple 
biochemical signals, and are involved in a wide variety of cellular processes such as 
proliferation, differentiation, transcription regulation and development. These kinases are 
activated by various environmental stresses and proinflammatory cytokines. The roles of 
this kinase in stress are related transcription and cell cycle regulation, as well as in 
genotoxic stress response (Wei et al., 2008). In particular, it is known that autophagy is 
induced by the release of BECN1 from BCL2 by phosphorylation of BCL2 by 
MAPK8/JNK1 (at Thr69, Ser70 and Ser87).  
Other autophagy related genes significantly up-regulated only by TG exposure are 
ULK1, BNIP3, p62/SQSTM1 and EIF2AK3. ULK family is composed by three related 
serine/threonine kinases: UNC-51-like kinase -1, -2, and -3 (ULK1, ULK2, UKL3). 
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ULK1 and ULK2 form a large complex, Atg1/ULK, that plays a  role in the initiation of 
autophagy: receiving signals of cellular nutrient status, recruiting downstream Atg 
proteins to the autophagosome formation site, and governing autophagosome formation 
(Mizushima, 2010).  
BNIP3 (BCL2/adenovirus E1B 19kDa interacting protein 3) is an autophagy 
receptor that signals autophagic degradation of mitochondria (mitophagy) via interaction 
of its LC3-interacting region (LIR) with Atg8 proteins (Zhu et al., 2013). Mammalian 
sequestosome 1 (p62/SQSTM1) is a multifunctional ubiquitin-binding scaffolding protein 
that serves multiple cellular functions ranging from cell signaling to autophagy. p62 
appears to be important for the clearance of proteins through autophagy. It was reported 
that self-oligomerization of p62 is important for its localization to the autophagosome 
formation site that is associated to the endoplasmic reticulum and it is recruited to early 
autophagic structures independentently of LC3 (Nezis and Stenmark, 2012).  
EIF2AK3 phosphorylates the alpha subunit of eukaryotic translation-initiation factor 
2 (EIF2), leading to its inactivation, and thus to a rapid reduction of translational 
initiation and repression of global protein synthesis. It is a type I membrane protein 
located in the endoplasmic reticulum (ER), where it is induced by ER stress caused by 
misfolded proteins. It is gene invoved in induction of autophagy (Zhao et al., 2013). 
TCDD exposure  induced the downregulation of AKT1 (V-akt murine thymoma 
viral oncogene homolog 1) gene expression. Akt is  a serine-threonine protein kinase 
known to inhibit autophagy (Yang et al., 2013). Our result was in accordance with 
literature (Chen et al., 2012). In fact, Chen and collegues observed that TCDD promoted 
breast cancer cell proliferation through the inactivation of Akt–FoxO3a signaling. 
We demonstrated  for the first time that TCDD exposure positively regulated 
autophagy in PC3 cells by modulating the following autophagy-related genes: PIK3C3, 
BECN-1, AMBRA1, MAP1LC3B, ATG4A, ATG4C, ATG5, ATG7, ATG10, 
ATG16L1, GABARAPL1, PRKAA, WIPI-1,MAPK8, MAPK14, and AKT1. 
Interestengly, these genes are present in different subnetworks composing the autophagy 
interactive network (Fig. 18) suggesting a multiple effect of TCDD on autophagy 
machinery. In particular, TCDD exposure positively influence autophagy system by 
upregulating autophagy genes having roles in the following networks: PlKC3-BECN1, 
ATG2-WIPI, UBL conjuction system, human ATG8’s and AMP kinase (Fig. 17 and 
Fig. 8A). Also, for the first time, we demonstrated that TCDD negatively influenced 
genes that are autophagy inhibitors, such as, AKT1 and BCL2. Therefore, our data 
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suggested that autophagy induction by TCDD exposure positively modulated autophagy 
inductors and negatively modulated autophagy inhibitors (Fig 17 and Table 1). 
These results were in agreement with the results obtained by exposing PC3 to TG, a 
known inductor of autophagy. TG induced autophagy positively influences autophagy 
system by upregulating autophagy genes having roles in the following networks: ULK1 
kinase, PlKC3-BECN1, ATG2-WIPI, UBL conjuction system and ATG8's (Fig. 17 and 
Fig 8A). Also, we demonstrated that TCDD negatively influenced a gene that is 
autophagy inhibitor, as AKT1(Fig 17 and Table 1). 
Future transcriptomics and pathways studies will further analyze the molecular 
influence of TCDD exposure after a larger window of hours on autophagy machinery. 
TCDD exposure upregulated also the Tumor necrosis factor (TNF) gene. TNF is a 
pleiotropic cytokine involved in the regulation of a wide spectrum of biological processes 
including cell proliferation, differentiation, apoptosis, lipid metabolism and coagulation 
with dual roles in cancer biology. In fact, despite its name, discovery history and approval 
as anticancer agent but TNF has been also implicated in cancer development and 
progression (Mocellin, 2008).  It was demostrated that high TNF levels have been related 
to prostate cancer progression via stimulation of proliferation, survival of malignant cells 
and increased resistance to chemotherapeutic agents (Srinivasan et al., 2010). Our result 
were in agreement with a previous study that demonstrated the property of TCDD to 
induce TNF (Massa et al., 1992). So we suggested a new role of plausible mechanism for 
TCDD-induced stimulation of proliferation and tumor  progression. 
Our results showed also that TCDD significativly decreased the expression of anti-
apoptotic genes (Bcl-2, Bcl-2L1) but it does not significantly upregulate caspases. Our 
results are in agreement with the fact that, in normal conditions, BECN1 is inhibited by 
its binding to the anti-apoptotic protein BCL2 (Pattingre et al., 2005). This results 
suggested that TCDD might regulate autophagy in PC3 by targeting different pathways 
leading to the enhancement of the autophagy system and negatively modulating pathways 
leading to the inhibibition of autophay. On the other hand, TG exposure upregulated  
caspase 3 and 8 (Fig.17), in agreement with the known fact that TG is an inductor not 
only of autophay but also of apopotosis (Chandrika et al., 2010). 
Interestingly, we noticed a shift of expression for tumor suppressor genes CDKN2A, 
RB1 in PC3 cells exposed either to TCDD or TG. In fact, while these two genes were 
significantly downregulated after TCDD exposure, they are significantly upregulated 
after TG treatment. A similar situation was encountered in another publication where it 
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was demonstrated that TCDD expsoure significantly increased the lung tumor incidence 
by diminishing CDKNA mRNA levels in female lung cancer mice (Wang et al., 2011). 
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CONCLUSIONS 
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Herein, we studied the influences of TCDD on PC3, a prostate cancer cell line. Our 
data showed, for the first time, that TCDD exerts its effects in PC3 by: enhancing cell 
proliferation, inducing cell cycle progression and cell morphology changes (a large 
number of cells with an elevated degree of vacuolization, characteristic sign of 
autophagy), increasing both gene expression and protein levels of LC3, that provided 
correlative data relating to the induction of autophagy. 
Interestingly, we demonstrated that TCDD positively regulated genes that are present 
in different subnetworks composing the autophagy interactive network (Fig. 8A) 
suggesting a multiple effect of TCDD on autophagy machinery.  In particular TCDD, in 
PC3 cells, modulated the following autophagy-related genes: PIK3C3, BECN-1, 
AMBRA1, MAP1LC3B, ATG4A, ATG4C, ATG7, ATG5, ATG10, ATG16L1, 
GABARAPL1, PRKAA, WIPI-1. 
Generally, autophagy was classified for a long time as form of programmed cell 
death; however accumulating evidence revealed that, while apoptosis is an irreversible 
way to cell death, autophagic cells often survives since autophagy leads to energy 
production to sustain survival upon severe stress (Chen and Karantza, 2011). 
Furthermore, we demostrated that TCDD exposure upregulated also TNF gene and 
high TNF levels have been related to prostate cancer progression via stimulation of 
proliferation, survival of malignant cells and increased resistance to chemotherapeutic 
agents (Srinivasan et al., 2010) suggesting a role of plausible mechanism for TCDD-
induced tumor progression.  
A correlation between incidences of cancer and the presence of industrial and toxic 
waste landfills was found in some areas of Campania Region (South Italy) (Barba et al., 
2011). Cancer mortality descriptive studies demonstrated an increase of incidences rates 
of the prostate cancer in the same areas where dioxin levels were elevated (Goldberg et 
al., 1995). Furthermore, studies performed in animal model suggested that TCDD 
exposure is associated with abnormal prostate development, altered prostate pathology 
and increase susceptibility to prostate cancer (Theobald and Peterson, 1997; Fritz et al., 
2005; Everly et al., 2009).  
More studies are needed to further confirm our data and ultimately to better clarify 
the role of autophagy in prostate cancer but herein, from our results we can declare that 
TCDD, may induce prostate cancer progression by: enhancing cell proliferation, 
inducing autophagy, deregulating the expression of genes related to the autophagy 
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machinery, and upregulating TNF resulting in an increased risk for both animal and 
human health.  
64  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES  
 
 
 
 
 
 
 
 
  
 
65  
 
Abbott, B. D., L. S. Birnbaum and R. M. Pratt (1987). "TCDD-induced hyperplasia of the 
ureteral epithelium produces hydronephrosis in murine fetuses." Teratology 35(3): 329-334. 
Ahn, N. S., H. Hu, J. S. Park, J. S. Park, J. S. Kim, S. An, G. Kong, O. I. Aruoma, Y. S. 
Lee and K. S. Kang (2005). "Molecular mechanisms of the 2,3,7,8-tetrachlorodibenzo-p-
dioxin-induced inverted U-shaped dose responsiveness in anchorage independent growth and 
cell proliferation of human breast epithelial cells with stem cell characteristics." Mutat Res 
579(1-2): 189-199. 
Andersson, P., J. McGuire, C. Rubio, K. Gradin, M. L. Whitelaw, S. Pettersson, A. 
Hanberg and L. Poellinger (2002). "A constitutively active dioxin/aryl hydrocarbon receptor 
induces stomach tumors." Proc Natl Acad Sci U S A 99(15): 9990-9995. 
Apel, A., I. Herr, H. Schwarz, H. P. Rodemann and A. Mayer (2008). "Blocked autophagy 
sensitizes resistant carcinoma cells to radiation therapy." Cancer Res 68(5): 1485-1494. 
Barba, M., A. Mazza, C. Guerriero, M. Di Maio, F. Romeo, P. Maranta, I. R. Marino, M. 
G. Paggi and A. Giordano (2011). "Wasting lives: the effects of toxic waste exposure on 
health. The case of Campania, Southern Italy." Cancer Biol Ther 12(2): 106-111. 
Barbieri, S., C. Pirovano, G. Scarlato, P. Tarchini, A. Zappa and M. Maranzana (1988). 
"Long-term effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the peripheral nervous system. 
Clinical and neurophysiological controlled study on subjects with chloracne from the Seveso 
area." Neuroepidemiology 7(1): 29-37. 
Basinger, R.R., Rawlings, C.A., Barsanti, J.A., Oliver, J.E. Jr, Crowell, W.A. (1987). 
"Urodynamic alterations after prostatectomy in dogs without clinical prostatic disease."Vet 
Surg 16(6):405-10. 
Behrends, C., M. E. Sowa, S. P. Gygi and J. W. Harper (2010). "Network organization of 
the human autophagy system." Nature 466(7302): 68-76. 
Bell, F.W., Klausner, J.S., Hayden, D.W., Feeney, D.A., Johnston, S.D. (1991). "Clinical 
and pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 
cases (1970-1987)." J Am Vet Med Assoc 199(11):1623-30. 
Birnbaum, L. S. and M. J. DeVito (1995). "Use of toxic equivalency factors for risk 
assessment for dioxins and related compounds." Toxicology 105(2-3): 391-401. 
Birnbaum, L. S., H. Weber, M. W. Harris, J. C. t. Lamb and J. D. McKinney (1985). 
"Toxic interaction of specific polychlorinated biphenyls and 2,3,7,8-tetrachlorodibenzo-p-
dioxin: increased incidence of cleft palate in mice." Toxicol Appl Pharmacol 77(2): 292-302. 
Bisanti, L., F. Bonetti, F. Caramaschi, G. Del Corno, C. Favaretti, S. E. Giambelluca, E. 
Marni, E. Montesarchio, V. Puccinelli, G. Remotti, C. Volpato, E. Zambrelli and G. M. Fara 
(1980). "Experiences from the accident of Seveso." Acta Morphol Acad Sci Hung 28(1-2): 
139-157. 
Bock, K. W. (1994). "Aryl hydrocarbon or dioxin receptor: biologic and toxic responses." 
Rev Physiol Biochem Pharmacol 125: 1-42. 
66  
 
Brown, N. M., P. A. Manzolillo, J. X. Zhang, J. Wang and C. A. Lamartiniere (1998). 
"Prenatal TCDD and predisposition to mammary cancer in the rat." Carcinogenesis 19(9): 
1623-1629. 
Budnick, L. D., J. N. Logue, D. C. Sokal, J. M. Fox and H. Falk (1984). "Cancer and birth 
defects near the Drake Superfund site, Pennsylvania." Arch Environ Health 39(6): 409-413. 
Burgio, S. L., F. Fabbri, I. J. Seymour, W. Zoli, D. Amadori and U. De Giorgi (2012). 
"Perspectives on mTOR inhibitors for castration-refractory prostate cancer." Curr Cancer 
Drug Targets 12(8): 940-949. 
Burleson, G. R., H. Lebrec, Y. G. Yang, J. D. Ibanes, K. N. Pennington and L. S. Birnbaum 
(1996). "Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on influenza virus host 
resistance in mice." Fundam Appl Toxicol 29(1): 40-47. 
Calkosinski, I., M. Dobrzynski, M. Cegielski, A. Sieja and M. Calkosinska (2006). "[The 
multifaceted effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in organisms, especially 
dentition changes]." Postepy Hig Med Dosw (Online) 60: 237-240. 
Chakrama, F. Z., S. Seguin-Py, J. N. Le Grand, A. Fraichard, R. Delage-Mourroux, G. 
Despouy, V. Perez, M. Jouvenot and M. Boyer-Guittaut (2010). "GABARAPL1 (GEC1) 
associates with autophagic vesicles." Autophagy 6(4). 
Chandrika, B. B., S. K. Maney, S. U. Lekshmi, J. Joseph, M. Seervi, S. P. K and R. S. T 
(2010). "Bax deficiency mediated drug resistance can be reversed by endoplasmic reticulum 
stress induced death signaling." Biochem Pharmacol 79(11): 1589-1599. 
Chen, F., C. C. Wang, E. Kim and L. E. Harrison (2008). "Hyperthermia in combination 
with oxidative stress induces autophagic cell death in HT-29 colon cancer cells." Cell Biol 
Int 32(7): 715-723. 
Chen, N. and V. Karantza (2011). "Autophagy as a therapeutic target in cancer." Cancer 
Biol Ther 11(2): 157-168. 
Chen, Y. J., C. M. Hung, N. Kay, C. C. Chen, Y. H. Kao and S. S. Yuan (2012). 
"Progesterone receptor is involved in 2,3,7,8-tetrachlorodibenzo-p-dioxin-stimulated breast 
cancer cells proliferation." Cancer Lett 319(2): 223-231. 
Cheng, C. K., Q. W. Fan and W. A. Weiss (2009). "PI3K signaling in glioma--animal 
models and therapeutic challenges." Brain Pathol 19(1): 112-120. 
Clark, G., A. Tritscher, D. Bell and G. Lucier (1992). "Integrated approach for evaluating 
species and interindividual differences in responsiveness to dioxins and structural analogs." 
Environ Health Perspect 98: 125-132. 
Comba, P., F. Bianchi, L. Fazzo, L. Martina, M. Menegozzo, F. Minichilli, F. Mitis, L. 
Musmeci, R. Pizzuti, M. Santoro, S. Trinca, M. Martuzzi and G. Health Impact of Waste 
Management Campania Working (2006). "Cancer mortality in an area of Campania (Italy) 
characterized by multiple toxic dumping sites." Ann N Y Acad Sci 1076: 449-461. 
 
67  
 
Cornell, K.K, Bostwick, D.G., Cooley, D.M., Hall, G., Harvey, H.J., Hendrick, M.J., Pauli, 
B.U., Render, J.A., Stoica, G., Sweet, D.C., Waters, D.J. (2000). "Clinical and pathologic 
aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases." 
Prostate 45(2):173-83. 
Cutler, J. J., G. S. Parker, S. Rosen, B. Prenney, R. Healey and G. G. Caldwell (1986). 
"Childhood leukemia in Woburn, Massachusetts." Public Health Rep 101(2): 201-205. 
Degenhardt, K., R. Mathew, B. Beaudoin, K. Bray, D. Anderson, G. Chen, C. Mukherjee, 
Y. Shi, C. Gelinas, Y. Fan, D. A. Nelson, S. Jin and E. White (2006). "Autophagy promotes 
tumor cell survival and restricts necrosis, inflammation, and tumorigenesis." Cancer Cell 
10(1): 51-64. 
Demarchi, F., C. Bertoli, T. Copetti, I. Tanida, C. Brancolini, E. L. Eskelinen and C. 
Schneider (2006). "Calpain is required for macroautophagy in mammalian cells." J Cell Biol 
175(4): 595-605. 
DeVito, M.J., Birnbaum, L.S., Farland, W.H., Gasiewicz, T.A., 1995. Comparisons of 
estimated human body burdens of dioxinlike chemicals and TCDD body burdens in 
experimentally exposed animals. Environ. Health Perspect. 103, 820–831. 
Diletti, G., Torreti, L., De Massis, M.R., Migliorati, G., Scortichini, G. (2003). "A case of 
milk contamination by PCDD/Fs in Italy: analytical levels and contamination source 
identification." Organohalogen. Compounds 64, 1–4. 
Dobrzyński, M., I. Całkosiński, I. Przywitowska, J. Kobierska-Brzoza, A. Czajczyńska-
Waszkiewicz, E. Sołtan and O. Parulska (2009). "Effects of Dioxins in Environmental 
Pollution on Development of Tooth Disorders." Pol. J. Environ. Stud. 18(3): 319-323. 
Eskelinen, E. L. and P. Saftig (2009). "Autophagy: a lysosomal degradation pathway with a 
central role in health and disease." Biochim Biophys Acta 1793(4): 664-673. 
Everly, L., G. S. Merrick, Z. A. Allen, W. M. Butler, K. Wallner, J. H. Lief, R. W. 
Galbreath and E. Adamovich (2009). "Prostate cancer control and survival in Vietnam 
veterans exposed to Agent Orange." Brachytherapy 8(1): 57-62. 
Fan, Y., G. P. Boivin, E. S. Knudsen, D. W. Nebert, Y. Xia and A. Puga (2010). "The aryl 
hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis." Cancer Res 
70(1): 212-220. 
Fiorito, F., R. Ciarcia, G. E. Granato, G. Marfe, V. Iovane, S. Florio, L. De Martino and U. 
Pagnini (2011). "2,3,7,8-tetrachlorodibenzo-p-dioxin induced autophagy in a bovine kidney 
cell line." Toxicology 290(2-3): 258-270. 
Fiorito, F., Marfè, G., Granato, G.E., Ciarcia, R., De Blasio, E., Tafani, M., Florio, S., De 
Martino, L., Muzi, G., Pagnini, U., Giordano, A., (2010). 2,3,7,8-Tetrachlorodibenzop-dioxin 
modifies expression and nuclear/cytosolic localization of bovine herpesvirus 1 immediate-
early protein (bICP0) during infection. J. Cell. Biochem. 111, 333–342. 
Fiorito, F., U. Pagnini, L. De Martino, S. Montagnaro, R. Ciarcia, S. Florio, M. Pacilio, A. 
Fucito, A. Rossi, G. Iovane and A. Giordano (2008a). "2,3,7,8-Tetrachlorodibenzo-p-dioxin 
68  
 
increases Bovine Herpesvirus type-1 (BHV-1) replication in Madin-Darby Bovine Kidney 
(MDBK) cells in vitro." J Cell Biochem 103(1): 221-233. 
Fiorito, F., Marfè, G., De Blasio, E., Granato, G.E., Tafani, M., De Martino, L., 
Montagnaro, S., Florio, S., Pagnini, U., (2008b). 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
regulates bovine herpesvirus type 1 induced apoptosis by modulating Bcl-2 family members. 
Apoptosis 13, 1243–1252. 
Flanagan, M. D., S. K. Whitehall and B. A. Morgan (2013). "An Atg10-like E2 enzyme is 
essential for cell cycle progression but not autophagy in Schizosaccharomyces pombe." Cell 
Cycle 12(2): 271-277. 
Fritz, W. A., T. M. Lin, R. W. Moore, P. S. Cooke and R. E. Peterson (2005). "In utero and 
lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure: effects on the prostate and its 
response to castration in senescent C57BL/6J mice." Toxicol Sci 86(2): 387-395. 
Giri, V. N., A. E. Cassidy, J. Beebe-Dimmer, L. Ellis, D. C. Smith, C. H. Bock and K. A. 
Cooney (2004). "Association between Agent Orange and prostate cancer: a pilot case-control 
study." Urology 63(4): 757-760; discussion 760-751. 
Goldberg, M. S., N. al-Homsi, L. Goulet and H. Riberdy (1995). "Incidence of cancer 
among persons living near a municipal solid waste landfill site in Montreal, Quebec." Arch 
Environ Health 50(6): 416-424. 
Greenlee, W. E., L. J. Hushka and D. R. Hushka (2001). "Molecular basis of dioxin 
actions: evidence supporting chemoprotection." Toxicol Pathol 29(1): 6-7. 
Gribble, G. W. (1994). "The abundant natural sources and uses of chlorinated chemicals." 
Am J Public Health 84(7): 1183. 
Griffith, J., R. C. Duncan, W. B. Riggan and A. C. Pellom (1989). "Cancer mortality in 
U.S. counties with hazardous waste sites and ground water pollution." Arch Environ Health 
44(2): 69-74. 
Grotemeier, A., S. Alers, S. G. Pfisterer, F. Paasch, M. Daubrawa, A. Dieterle, B. Viollet, 
S. Wesselborg, T. Proikas-Cezanne and B. Stork (2010). "AMPK-independent induction of 
autophagy by cytosolic Ca2+ increase." Cell Signal 22(6): 914-925. 
Huang Z, Chen, Q., Luck, D., Beckers, J., Wilson, B.C., Trncic, N., Larue, S.M., Blanc, D., 
Hetzel, F.W. (2005). "Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide 
(Tookad), in normal canine prostate and spontaneous canine prostate cancer." Lasers Surg 
Med 36(5):390-7. 
Huang, W. P., S. V. Scott, J. Kim and D. J. Klionsky (2000). "The itinerary of a vesicle 
component, Aut7p/Cvt5p, terminates in the yeast vacuole via the autophagy/Cvt pathways." J 
Biol Chem 275(8): 5845-5851. 
Huff, J., G. Lucier and A. Tritscher (1994). "Carcinogenicity of TCDD: experimental, 
mechanistic, and epidemiologic evidence." Annu Rev Pharmacol Toxicol 34: 343-372. 
Iannuzzi, L., A. Perucatti, G. P. Di Meo, F. Polimeno, F. Ciotola, D. Incarnato, V. Peretti, 
A. Caputi-Jambrenghi, A. Pecoraro, F. Manniti, A. D'Alessandro and G. Vonghia (2004). 
69  
 
"Chromosome fragility in two sheep flocks exposed to dioxins during pasturage." 
Mutagenesis 19(5): 355-359. 
Ito, H., S. Daido, T. Kanzawa, S. Kondo and Y. Kondo (2005). "Radiation-induced 
autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells." Int J 
Oncol 26(5): 1401-1410. 
Jaber, N., Z. Dou, J. S. Chen, J. Catanzaro, Y. P. Jiang, L. M. Ballou, E. Selinger, X. 
Ouyang, R. Z. Lin, J. Zhang and W. X. Zong (2012). "Class III PI3K Vps34 plays an 
essential role in autophagy and in heart and liver function." Proc Natl Acad Sci U S A 
109(6): 2003-2008. 
Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, 
Ohsumi Y, Yoshimori T. (2000). LC3, a mammalian homologue of yeast Apg8p, is localized 
in autophagosome membranes after processing. EMBO J. 19(21):5720-8.  
Kim, R. H., J. M. Coates, T. L. Bowles, G. P. McNerney, J. Sutcliffe, J. U. Jung, R. 
Gandour-Edwards, F. Y. Chuang, R. J. Bold and H. J. Kung (2009). "Arginine deiminase as a 
novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis." 
Cancer Res 69(2): 700-708. 
Klionsky, D. J. (2011). "For the last time, it is GFP-Atg8, not Atg8-GFP (and the same 
goes for LC3)." Autophagy 7(10): 1093-1094. 
Klionsky, D. J., F. C. Abdalla, H. Abeliovich, R. T. Abraham, A. Acevedo-Arozena, K. 
Adeli, L. Agholme, M. Agnello, P. Agostinis, J. A. Aguirre-Ghiso, H. J. Ahn, O. Ait-
Mohamed, S. Ait-Si-Ali, T. Akematsu, S. Akira, H. M. Al-Younes, M. A. Al-Zeer, M. L. 
Albert, R. L. Albin, J. Alegre-Abarrategui, M. F. Aleo, M. Alirezaei, A. Almasan, M. 
Almonte-Becerril, A. Amano, R. Amaravadi, S. Amarnath, A. O. Amer, N. Andrieu-Abadie, 
V. Anantharam, D. K. Ann, S. Anoopkumar-Dukie, H. Aoki, N. Apostolova, G. Arancia, J. 
P. Aris, K. Asanuma, N. Y. Asare, H. Ashida, V. Askanas, D. S. Askew, P. Auberger, M. 
Baba, S. K. Backues, E. H. Baehrecke, B. A. Bahr, X. Y. Bai, Y. Bailly, R. Baiocchi, G. 
Baldini, W. Balduini, A. Ballabio, B. A. Bamber, E. T. Bampton, G. Banhegyi, C. R. 
Bartholomew, D. C. Bassham, R. C. Bast, Jr., H. Batoko, B. H. Bay, I. Beau, D. M. Bechet, 
T. J. Begley, C. Behl, C. Behrends, S. Bekri, B. Bellaire, L. J. Bendall, L. Benetti, L. 
Berliocchi, H. Bernardi, F. Bernassola, S. Besteiro, I. Bhatia-Kissova, X. Bi, M. Biard-
Piechaczyk, J. S. Blum, L. H. Boise, P. Bonaldo, D. L. Boone, B. C. Bornhauser, K. R. 
Bortoluci, I. Bossis, F. Bost, J. P. Bourquin, P. Boya, M. Boyer-Guittaut, P. V. Bozhkov, N. 
R. Brady, C. Brancolini, A. Brech, J. E. Brenman, A. Brennand, E. H. Bresnick, P. Brest, D. 
Bridges, M. L. Bristol, P. S. Brookes, E. J. Brown, J. H. Brumell, N. Brunetti-Pierri, U. T. 
Brunk, D. E. Bulman, S. J. Bultman, G. Bultynck, L. F. Burbulla, W. Bursch, J. P. Butchar, 
W. Buzgariu, S. P. Bydlowski, K. Cadwell, M. Cahova, D. Cai, J. Cai, Q. Cai, B. Calabretta, 
J. Calvo-Garrido, N. Camougrand, M. Campanella, J. Campos-Salinas, E. Candi, L. Cao, A. 
B. Caplan, S. R. Carding, S. M. Cardoso, J. S. Carew, C. R. Carlin, V. Carmignac, L. A. 
Carneiro, S. Carra, R. A. Caruso, G. Casari, C. Casas, R. Castino, E. Cebollero, F. Cecconi, J. 
Celli, H. Chaachouay, H. J. Chae, C. Y. Chai, D. C. Chan, E. Y. Chan, R. C. Chang, C. M. 
Che, C. C. Chen, G. C. Chen, G. Q. Chen, M. Chen, Q. Chen, S. S. Chen, W. Chen, X. Chen, 
X. Chen, X. Chen, Y. G. Chen, Y. Chen, Y. Chen, Y. J. Chen, Z. Chen, A. Cheng, C. H. 
Cheng, Y. Cheng, H. Cheong, J. H. Cheong, S. Cherry, R. Chess-Williams, Z. H. Cheung, E. 
Chevet, H. L. Chiang, R. Chiarelli, T. Chiba, L. S. Chin, S. H. Chiou, F. V. Chisari, C. H. 
Cho, D. H. Cho, A. M. Choi, D. Choi, K. S. Choi, M. E. Choi, S. Chouaib, D. Choubey, V. 
70  
 
Choubey, C. T. Chu, T. H. Chuang, S. H. Chueh, T. Chun, Y. J. Chwae, M. L. Chye, R. 
Ciarcia, M. R. Ciriolo, M. J. Clague, R. S. Clark, P. G. Clarke, R. Clarke, P. Codogno, H. A. 
Coller, M. I. Colombo, S. Comincini, M. Condello, F. Condorelli, M. R. Cookson, G. H. 
Coombs, I. Coppens, R. Corbalan, P. Cossart, P. Costelli, S. Costes, A. Coto-Montes, E. 
Couve, F. P. Coxon, J. M. Cregg, J. L. Crespo, M. J. Cronje, A. M. Cuervo, J. J. Cullen, M. J. 
Czaja, M. D'Amelio, A. Darfeuille-Michaud, L. M. Davids, F. E. Davies, M. De Felici, J. F. 
de Groot, C. A. de Haan, L. De Martino, A. De Milito, V. De Tata, J. Debnath, A. Degterev, 
B. Dehay, L. M. Delbridge, F. Demarchi, Y. Z. Deng, J. Dengjel, P. Dent, D. Denton, V. 
Deretic, S. D. Desai, R. J. Devenish, M. Di Gioacchino, G. Di Paolo, C. Di Pietro, G. Diaz-
Araya, I. Diaz-Laviada, M. T. Diaz-Meco, J. Diaz-Nido, I. Dikic, S. P. Dinesh-Kumar, W. X. 
Ding, C. W. Distelhorst, A. Diwan, M. Djavaheri-Mergny, S. Dokudovskaya, Z. Dong, F. C. 
Dorsey, V. Dosenko, J. J. Dowling, S. Doxsey, M. Dreux, M. E. Drew, Q. Duan, M. A. 
Duchosal, K. Duff, I. Dugail, M. Durbeej, M. Duszenko, C. L. Edelstein, A. L. Edinger, G. 
Egea, L. Eichinger, N. T. Eissa, S. Ekmekcioglu, W. S. El-Deiry, Z. Elazar, M. Elgendy, L. 
M. Ellerby, K. E. Eng, A. M. Engelbrecht, S. Engelender, J. Erenpreisa, R. Escalante, A. 
Esclatine, E. L. Eskelinen, L. Espert, V. Espina, H. Fan, J. Fan, Q. W. Fan, Z. Fan, S. Fang, 
Y. Fang, M. Fanto, A. Fanzani, T. Farkas, J. C. Farre, M. Faure, M. Fechheimer, C. G. Feng, 
J. Feng, Q. Feng, Y. Feng, L. Fesus, R. Feuer, M. E. Figueiredo-Pereira, G. M. Fimia, D. C. 
Fingar, S. Finkbeiner, T. Finkel, K. D. Finley, F. Fiorito, E. A. Fisher, P. B. Fisher, M. 
Flajolet, M. L. Florez-McClure, S. Florio, E. A. Fon, F. Fornai, F. Fortunato, R. Fotedar, D. 
H. Fowler, H. S. Fox, R. Franco, L. B. Frankel, M. Fransen, J. M. Fuentes, J. Fueyo, J. Fujii, 
K. Fujisaki, E. Fujita, M. Fukuda, R. H. Furukawa, M. Gaestel, P. Gailly, M. Gajewska, B. 
Galliot, V. Galy, S. Ganesh, B. Ganetzky, I. G. Ganley, F. B. Gao, G. F. Gao, J. Gao, L. 
Garcia, G. Garcia-Manero, M. Garcia-Marcos, M. Garmyn, A. L. Gartel, E. Gatti, M. Gautel, 
T. R. Gawriluk, M. E. Gegg, J. Geng, M. Germain, J. E. Gestwicki, D. A. Gewirtz, S. 
Ghavami, P. Ghosh, A. M. Giammarioli, A. N. Giatromanolaki, S. B. Gibson, R. W. 
Gilkerson, M. L. Ginger, H. N. Ginsberg, J. Golab, M. S. Goligorsky, P. Golstein, C. Gomez-
Manzano, E. Goncu, C. Gongora, C. D. Gonzalez, R. Gonzalez, C. Gonzalez-Estevez, R. A. 
Gonzalez-Polo, E. Gonzalez-Rey, N. V. Gorbunov, S. Gorski, S. Goruppi, R. A. Gottlieb, D. 
Gozuacik, G. E. Granato, G. D. Grant, K. N. Green, A. Gregorc, F. Gros, C. Grose, T. W. 
Grunt, P. Gual, J. L. Guan, K. L. Guan, S. M. Guichard, A. S. Gukovskaya, I. Gukovsky, J. 
Gunst, A. B. Gustafsson, A. J. Halayko, A. N. Hale, S. K. Halonen, M. Hamasaki, F. Han, T. 
Han, M. K. Hancock, M. Hansen, H. Harada, M. Harada, S. E. Hardt, J. W. Harper, A. L. 
Harris, J. Harris, S. D. Harris, M. Hashimoto, J. A. Haspel, S. Hayashi, L. A. Hazelhurst, C. 
He, Y. W. He, M. J. Hebert, K. A. Heidenreich, M. H. Helfrich, G. V. Helgason, E. P. 
Henske, B. Herman, P. K. Herman, C. Hetz, S. Hilfiker, J. A. Hill, L. J. Hocking, P. Hofman, 
T. G. Hofmann, J. Hohfeld, T. L. Holyoake, M. H. Hong, D. A. Hood, G. S. Hotamisligil, E. 
J. Houwerzijl, M. Hoyer-Hansen, B. Hu, C. A. Hu, H. M. Hu, Y. Hua, C. Huang, J. Huang, S. 
Huang, W. P. Huang, T. B. Huber, W. K. Huh, T. H. Hung, T. R. Hupp, G. M. Hur, J. B. 
Hurley, S. N. Hussain, P. J. Hussey, J. J. Hwang, S. Hwang, A. Ichihara, S. Ilkhanizadeh, K. 
Inoki, T. Into, V. Iovane, J. L. Iovanna, N. Y. Ip, Y. Isaka, H. Ishida, C. Isidoro, K. Isobe, A. 
Iwasaki, M. Izquierdo, Y. Izumi, P. M. Jaakkola, M. Jaattela, G. R. Jackson, W. T. Jackson, 
B. Janji, M. Jendrach, J. H. Jeon, E. B. Jeung, H. Jiang, H. Jiang, J. X. Jiang, M. Jiang, Q. 
Jiang, X. Jiang, X. Jiang, A. Jimenez, M. Jin, S. Jin, C. O. Joe, T. Johansen, D. E. Johnson, 
G. V. Johnson, N. L. Jones, B. Joseph, S. K. Joseph, A. M. Joubert, G. Juhasz, L. Juillerat-
Jeanneret, C. H. Jung, Y. K. Jung, K. Kaarniranta, A. Kaasik, T. Kabuta, M. Kadowaki, K. 
Kagedal, Y. Kamada, V. O. Kaminskyy, H. H. Kampinga, H. Kanamori, C. Kang, K. B. 
Kang, K. I. Kang, R. Kang, Y. A. Kang, T. Kanki, T. D. Kanneganti, H. Kanno, A. G. 
Kanthasamy, A. Kanthasamy, V. Karantza, G. P. Kaushal, S. Kaushik, Y. Kawazoe, P. Y. 
Ke, J. H. Kehrl, A. Kelekar, C. Kerkhoff, D. H. Kessel, H. Khalil, J. A. Kiel, A. A. Kiger, A. 
71  
 
Kihara, D. R. Kim, D. H. Kim, D. H. Kim, E. K. Kim, H. R. Kim, J. S. Kim, J. H. Kim, J. C. 
Kim, J. K. Kim, P. K. Kim, S. W. Kim, Y. S. Kim, Y. Kim, A. Kimchi, A. C. Kimmelman, J. 
S. King, T. J. Kinsella, V. Kirkin, L. A. Kirshenbaum, K. Kitamoto, K. Kitazato, L. Klein, 
W. T. Klimecki, J. Klucken, E. Knecht, B. C. Ko, J. C. Koch, H. Koga, J. Y. Koh, Y. H. Koh, 
M. Koike, M. Komatsu, E. Kominami, H. J. Kong, W. J. Kong, V. I. Korolchuk, Y. Kotake, 
M. I. Koukourakis, J. B. Kouri Flores, A. L. Kovacs, C. Kraft, D. Krainc, H. Kramer, C. 
Kretz-Remy, A. M. Krichevsky, G. Kroemer, R. Kruger, O. Krut, N. T. Ktistakis, C. Y. 
Kuan, R. Kucharczyk, A. Kumar, R. Kumar, S. Kumar, M. Kundu, H. J. Kung, T. Kurz, H. J. 
Kwon, A. R. La Spada, F. Lafont, T. Lamark, J. Landry, J. D. Lane, P. Lapaquette, J. F. 
Laporte, L. Laszlo, S. Lavandero, J. N. Lavoie, R. Layfield, P. A. Lazo, W. Le, L. Le Cam, 
D. J. Ledbetter, A. J. Lee, B. W. Lee, G. M. Lee, J. Lee, J. H. Lee, M. Lee, M. S. Lee, S. H. 
Lee, C. Leeuwenburgh, P. Legembre, R. Legouis, M. Lehmann, H. Y. Lei, Q. Y. Lei, D. A. 
Leib, J. Leiro, J. J. Lemasters, A. Lemoine, M. S. Lesniak, D. Lev, V. V. Levenson, B. 
Levine, E. Levy, F. Li, J. L. Li, L. Li, S. Li, W. Li, X. J. Li, Y. B. Li, Y. P. Li, C. Liang, Q. 
Liang, Y. F. Liao, P. P. Liberski, A. Lieberman, H. J. Lim, K. L. Lim, K. Lim, C. F. Lin, F. 
C. Lin, J. Lin, J. D. Lin, K. Lin, W. W. Lin, W. C. Lin, Y. L. Lin, R. Linden, P. Lingor, J. 
Lippincott-Schwartz, M. P. Lisanti, P. B. Liton, B. Liu, C. F. Liu, K. Liu, L. Liu, Q. A. Liu, 
W. Liu, Y. C. Liu, Y. Liu, R. A. Lockshin, C. N. Lok, S. Lonial, B. Loos, G. Lopez-
Berestein, C. Lopez-Otin, L. Lossi, M. T. Lotze, P. Low, B. Lu, B. Lu, B. Lu, Z. Lu, F. 
Luciano, N. W. Lukacs, A. H. Lund, M. A. Lynch-Day, Y. Ma, F. Macian, J. P. MacKeigan, 
K. F. Macleod, F. Madeo, L. Maiuri, M. C. Maiuri, D. Malagoli, M. C. Malicdan, W. 
Malorni, N. Man, E. M. Mandelkow, S. Manon, I. Manov, K. Mao, X. Mao, Z. Mao, P. 
Marambaud, D. Marazziti, Y. L. Marcel, K. Marchbank, P. Marchetti, S. J. Marciniak, M. 
Marcondes, M. Mardi, G. Marfe, G. Marino, M. Markaki, M. R. Marten, S. J. Martin, C. 
Martinand-Mari, W. Martinet, M. Martinez-Vicente, M. Masini, P. Matarrese, S. Matsuo, R. 
Matteoni, A. Mayer, N. M. Mazure, D. J. McConkey, M. J. McConnell, C. McDermott, C. 
McDonald, G. M. McInerney, S. L. McKenna, B. McLaughlin, P. J. McLean, C. R. 
McMaster, G. A. McQuibban, A. J. Meijer, M. H. Meisler, A. Melendez, T. J. Melia, G. 
Melino, M. A. Mena, J. A. Menendez, R. F. Menna-Barreto, M. B. Menon, F. M. Menzies, C. 
A. Mercer, A. Merighi, D. E. Merry, S. Meschini, C. G. Meyer, T. F. Meyer, C. Y. Miao, J. 
Y. Miao, P. A. Michels, C. Michiels, D. Mijaljica, A. Milojkovic, S. Minucci, C. Miracco, C. 
K. Miranti, I. Mitroulis, K. Miyazawa, N. Mizushima, B. Mograbi, S. Mohseni, X. Molero, 
B. Mollereau, F. Mollinedo, T. Momoi, I. Monastyrska, M. M. Monick, M. J. Monteiro, M. 
N. Moore, R. Mora, K. Moreau, P. I. Moreira, Y. Moriyasu, J. Moscat, S. Mostowy, J. C. 
Mottram, T. Motyl, C. E. Moussa, S. Muller, S. Muller, K. Munger, C. Munz, L. O. Murphy, 
M. E. Murphy, A. Musaro, I. Mysorekar, E. Nagata, K. Nagata, A. Nahimana, U. Nair, T. 
Nakagawa, K. Nakahira, H. Nakano, H. Nakatogawa, M. Nanjundan, N. I. Naqvi, D. P. 
Narendra, M. Narita, M. Navarro, S. T. Nawrocki, T. Y. Nazarko, A. Nemchenko, M. G. 
Netea, T. P. Neufeld, P. A. Ney, I. P. Nezis, H. P. Nguyen, D. Nie, I. Nishino, C. Nislow, R. 
A. Nixon, T. Noda, A. A. Noegel, A. Nogalska, S. Noguchi, L. Notterpek, I. Novak, T. 
Nozaki, N. Nukina, T. Nurnberger, B. Nyfeler, K. Obara, T. D. Oberley, S. Oddo, M. Ogawa, 
T. Ohashi, K. Okamoto, N. L. Oleinick, F. J. Oliver, L. J. Olsen, S. Olsson, O. Opota, T. F. 
Osborne, G. K. Ostrander, K. Otsu, J. H. Ou, M. Ouimet, M. Overholtzer, B. Ozpolat, P. 
Paganetti, U. Pagnini, N. Pallet, G. E. Palmer, C. Palumbo, T. Pan, T. Panaretakis, U. B. 
Pandey, Z. Papackova, I. Papassideri, I. Paris, J. Park, O. K. Park, J. B. Parys, K. R. Parzych, 
S. Patschan, C. Patterson, S. Pattingre, J. M. Pawelek, J. Peng, D. H. Perlmutter, I. Perrotta, 
G. Perry, S. Pervaiz, M. Peter, G. J. Peters, M. Petersen, G. Petrovski, J. M. Phang, M. 
Piacentini, P. Pierre, V. Pierrefite-Carle, G. Pierron, R. Pinkas-Kramarski, A. Piras, N. Piri, 
L. C. Platanias, S. Poggeler, M. Poirot, A. Poletti, C. Pous, M. Pozuelo-Rubio, M. Praetorius-
Ibba, A. Prasad, M. Prescott, M. Priault, N. Produit-Zengaffinen, A. Progulske-Fox, T. 
72  
 
Proikas-Cezanne, S. Przedborski, K. Przyklenk, R. Puertollano, J. Puyal, S. B. Qian, L. Qin, 
Z. H. Qin, S. E. Quaggin, N. Raben, H. Rabinowich, S. W. Rabkin, I. Rahman, A. Rami, G. 
Ramm, G. Randall, F. Randow, V. A. Rao, J. C. Rathmell, B. Ravikumar, S. K. Ray, B. H. 
Reed, J. C. Reed, F. Reggiori, A. Regnier-Vigouroux, A. S. Reichert, J. J. Reiners, Jr., R. J. 
Reiter, J. Ren, J. L. Revuelta, C. J. Rhodes, K. Ritis, E. Rizzo, J. Robbins, M. Roberge, H. 
Roca, M. C. Roccheri, S. Rocchi, H. P. Rodemann, S. Rodriguez de Cordoba, B. Rohrer, I. B. 
Roninson, K. Rosen, M. M. Rost-Roszkowska, M. Rouis, K. M. Rouschop, F. Rovetta, B. P. 
Rubin, D. C. Rubinsztein, K. Ruckdeschel, E. B. Rucker, 3rd, A. Rudich, E. Rudolf, N. Ruiz-
Opazo, R. Russo, T. E. Rusten, K. M. Ryan, S. W. Ryter, D. M. Sabatini, J. Sadoshima, T. 
Saha, T. Saitoh, H. Sakagami, Y. Sakai, G. H. Salekdeh, P. Salomoni, P. M. Salvaterra, G. 
Salvesen, R. Salvioli, A. M. Sanchez, J. A. Sanchez-Alcazar, R. Sanchez-Prieto, M. Sandri, 
U. Sankar, P. Sansanwal, L. Santambrogio, S. Saran, S. Sarkar, M. Sarwal, C. Sasakawa, A. 
Sasnauskiene, M. Sass, K. Sato, M. Sato, A. H. Schapira, M. Scharl, H. M. Schatzl, W. 
Scheper, S. Schiaffino, C. Schneider, M. E. Schneider, R. Schneider-Stock, P. V. Schoenlein, 
D. F. Schorderet, C. Schuller, G. K. Schwartz, L. Scorrano, L. Sealy, P. O. Seglen, J. Segura-
Aguilar, I. Seiliez, O. Seleverstov, C. Sell, J. B. Seo, D. Separovic, V. Setaluri, T. Setoguchi, 
C. Settembre, J. J. Shacka, M. Shanmugam, I. M. Shapiro, E. Shaulian, R. J. Shaw, J. H. 
Shelhamer, H. M. Shen, W. C. Shen, Z. H. Sheng, Y. Shi, K. Shibuya, Y. Shidoji, J. J. Shieh, 
C. M. Shih, Y. Shimada, S. Shimizu, T. Shintani, O. S. Shirihai, G. C. Shore, A. A. Sibirny, 
S. B. Sidhu, B. Sikorska, E. C. Silva-Zacarin, A. Simmons, A. K. Simon, H. U. Simon, C. 
Simone, A. Simonsen, D. A. Sinclair, R. Singh, D. Sinha, F. A. Sinicrope, A. Sirko, P. M. 
Siu, E. Sivridis, V. Skop, V. P. Skulachev, R. S. Slack, S. S. Smaili, D. R. Smith, M. S. 
Soengas, T. Soldati, X. Song, A. K. Sood, T. W. Soong, F. Sotgia, S. A. Spector, C. D. Spies, 
W. Springer, S. M. Srinivasula, L. Stefanis, J. S. Steffan, R. Stendel, H. Stenmark, A. 
Stephanou, S. T. Stern, C. Sternberg, B. Stork, P. Stralfors, C. S. Subauste, X. Sui, D. Sulzer, 
J. Sun, S. Y. Sun, Z. J. Sun, J. J. Sung, K. Suzuki, T. Suzuki, M. S. Swanson, C. Swanton, S. 
T. Sweeney, L. K. Sy, G. Szabadkai, I. Tabas, H. Taegtmeyer, M. Tafani, K. Takacs-Vellai, 
Y. Takano, K. Takegawa, G. Takemura, F. Takeshita, N. J. Talbot, K. S. Tan, K. Tanaka, K. 
Tanaka, D. Tang, D. Tang, I. Tanida, B. A. Tannous, N. Tavernarakis, G. S. Taylor, G. A. 
Taylor, J. P. Taylor, L. S. Terada, A. Terman, G. Tettamanti, K. Thevissen, C. B. Thompson, 
A. Thorburn, M. Thumm, F. Tian, Y. Tian, G. Tocchini-Valentini, A. M. Tolkovsky, Y. 
Tomino, L. Tonges, S. A. Tooze, C. Tournier, J. Tower, R. Towns, V. Trajkovic, L. H. 
Travassos, T. F. Tsai, M. P. Tschan, T. Tsubata, A. Tsung, B. Turk, L. S. Turner, S. C. Tyagi, 
Y. Uchiyama, T. Ueno, M. Umekawa, R. Umemiya-Shirafuji, V. K. Unni, M. I. Vaccaro, E. 
M. Valente, G. Van den Berghe, I. J. van der Klei, W. van Doorn, L. F. van Dyk, M. van 
Egmond, L. A. van Grunsven, P. Vandenabeele, W. P. Vandenberghe, I. Vanhorebeek, E. C. 
Vaquero, G. Velasco, T. Vellai, J. M. Vicencio, R. D. Vierstra, M. Vila, C. Vindis, G. Viola, 
M. T. Viscomi, O. V. Voitsekhovskaja, C. von Haefen, M. Votruba, K. Wada, R. Wade-
Martins, C. L. Walker, C. M. Walsh, J. Walter, X. B. Wan, A. Wang, C. Wang, D. Wang, F. 
Wang, F. Wang, G. Wang, H. Wang, H. G. Wang, H. D. Wang, J. Wang, K. Wang, M. 
Wang, R. C. Wang, X. Wang, X. Wang, Y. J. Wang, Y. Wang, Z. Wang, Z. C. Wang, Z. 
Wang, D. G. Wansink, D. M. Ward, H. Watada, S. L. Waters, P. Webster, L. Wei, C. C. 
Weihl, W. A. Weiss, S. M. Welford, L. P. Wen, C. A. Whitehouse, J. L. Whitton, A. J. 
Whitworth, T. Wileman, J. W. Wiley, S. Wilkinson, D. Willbold, R. L. Williams, P. R. 
Williamson, B. G. Wouters, C. Wu, D. C. Wu, W. K. Wu, A. Wyttenbach, R. J. Xavier, Z. 
Xi, P. Xia, G. Xiao, Z. Xie, Z. Xie, D. Z. Xu, J. Xu, L. Xu, X. Xu, A. Yamamoto, A. 
Yamamoto, S. Yamashina, M. Yamashita, X. Yan, M. Yanagida, D. S. Yang, E. Yang, J. M. 
Yang, S. Y. Yang, W. Yang, W. Y. Yang, Z. Yang, M. C. Yao, T. P. Yao, B. Yeganeh, W. L. 
Yen, J. J. Yin, X. M. Yin, O. J. Yoo, G. Yoon, S. Y. Yoon, T. Yorimitsu, Y. Yoshikawa, T. 
Yoshimori, K. Yoshimoto, H. J. You, R. J. Youle, A. Younes, L. Yu, L. Yu, S. W. Yu, W. H. 
73  
 
Yu, Z. M. Yuan, Z. Yue, C. H. Yun, M. Yuzaki, O. Zabirnyk, E. Silva-Zacarin, D. Zacks, E. 
Zacksenhaus, N. Zaffaroni, Z. Zakeri, H. J. Zeh, 3rd, S. O. Zeitlin, H. Zhang, H. L. Zhang, J. 
Zhang, J. P. Zhang, L. Zhang, L. Zhang, M. Y. Zhang, X. D. Zhang, M. Zhao, Y. F. Zhao, Y. 
Zhao, Z. J. Zhao, X. Zheng, B. Zhivotovsky, Q. Zhong, C. Z. Zhou, C. Zhu, W. G. Zhu, X. F. 
Zhu, X. Zhu, Y. Zhu, T. Zoladek, W. X. Zong, A. Zorzano, J. Zschocke and B. Zuckerbraun 
(2012). "Guidelines for the use and interpretation of assays for monitoring autophagy." 
Autophagy 8(4): 445-544. 
Knutsen, A. P. (1984). "Immunologic effects of TCDD exposure in humans." Bull Environ 
Contam Toxicol 33(6): 673-681. 
Kroemer, G., G. Marino and B. Levine (2010). "Autophagy and the integrated stress 
response." Mol Cell 40(2): 280-293. 
Lamoureux, F., C. Thomas, C. Crafter, M. Kumano, F. Zhang, B. R. Davies, M. E. Gleave 
and A. Zoubeidi (2013). "Blocked Autophagy Using Lysosomotropic Agents Sensitizes 
Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363." Clin Cancer Res 
19(4): 833-844. 
Leroy, B.E., Northrup, N. (2008). Prostate cancer in dogs: comparative and clinical aspects. 
Vet J. 180(2):149-62.  
Levine, B. and D. J. Klionsky (2004). "Development by self-digestion: molecular 
mechanisms and biological functions of autophagy." Dev Cell 6(4): 463-477. 
Li, B. X., C. Y. Li, R. Q. Peng, X. J. Wu, H. Y. Wang, D. S. Wan, X. F. Zhu and X. S. 
Zhang (2009). "The expression of beclin 1 is associated with favorable prognosis in stage 
IIIB colon cancers." Autophagy 5(3): 303-306. 
Lin, T. M., K. Ko, R. W. Moore, D. L. Buchanan, P. S. Cooke and R. E. Peterson (2001). 
"Role of the aryl hydrocarbon receptor in the development of control and 2,3,7,8-
tetrachlorodibenzo-p-dioxin-exposed male mice." J Toxicol Environ Health A 64(4): 327-
342. 
Lin, T. M., N. T. Rasmussen, R. W. Moore, R. M. Albrecht and R. E. Peterson (2003). 
"Region-specific inhibition of prostatic epithelial bud formation in the urogenital sinus of 
C57BL/6 mice exposed in utero to 2,3,7,8-tetrachlorodibenzo-p-dioxin." Toxicol Sci 76(1): 
171-181. 
Lin, T. M., U. Simanainen, R. W. Moore and R. E. Peterson (2002). "Critical windows of 
vulnerability for effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on prostate and seminal 
vesicle development in C57BL/6 mice." Toxicol Sci 69(1): 202-209. 
Loertscher, J. A., T. M. Lin, R. E. Peterson and B. L. Allen-Hoffmann (2002). "In utero 
exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin causes accelerated terminal differentiation in 
fetal mouse skin." Toxicol Sci 68(2): 465-472. 
Lotz, I., H. Brand and E. Greiser (1991). "Increase in the incidence of leukemia in the area 
of a former hazardous waste site." Offentl Gesundheitswes 53(8-9): 579-580. 
Maiuri, M. C., E. Zalckvar, A. Kimchi and G. Kroemer (2007). "Self-eating and self-
killing: crosstalk between autophagy and apoptosis." Nat Rev Mol Cell Biol 8(9): 741-752. 
74  
 
Mallin, K. (1990). "Investigation of a bladder cancer cluster in northwestern Illinois." Am J 
Epidemiol 132(1 Suppl): S96-106. 
Mandal, P. K. (2005). "Dioxin: a review of its environmental effects and its aryl 
hydrocarbon receptor biology." J Comp Physiol B 175(4): 221-230. 
Manz, A., J. Berger, J. H. Dwyer, D. Flesch-Janys, S. Nagel and H. Waltsgott (1991). 
"Cancer mortality among workers in chemical plant contaminated with dioxin." Lancet 
338(8773): 959-964. 
Markman, B., R. Dienstmann and J. Tabernero (2010). "Targeting the PI3K/Akt/mTOR 
pathway--beyond rapalogs." Oncotarget 1(7): 530-543. 
Massa, T., A. Esmaeili, H. Fortmeyer, B. Schlatterer, H. Hagenmaier and P. Chandra 
(1992). "Cell transforming and oncogenic activity of 2,3,7,8--tetrachloro--and 2,3,7,8 
tetrabromodibenzo-p-dioxin." Anticancer Res 12(6B): 2053-2060. 
Mathew, R., S. Kongara, B. Beaudoin, C. M. Karp, K. Bray, K. Degenhardt, G. Chen, S. 
Jin and E. White (2007). "Autophagy suppresses tumor progression by limiting chromosomal 
instability." Genes Dev 21(11): 1367-1381. 
Messing, E. M., J. Manola, M. Sarosdy, G. Wilding, E. D. Crawford and D. Trump (1999). 
"Immediate hormonal therapy compared with observation after radical prostatectomy and 
pelvic lymphadenectomy in men with node-positive prostate cancer." N Engl J Med 341(24): 
1781-1788. 
Michalek, J. E., A. J. Rahe, P. M. Kulkarni and R. C. Tripathi (1998). "Levels of 2,3,7,8-
tetrachlorodibenzo-p-dioxin in 1,302 unexposed Air Force Vietnam-era veterans." J Expo 
Anal Environ Epidemiol 8(1): 59-64. 
Miracco, C., E. Cosci, G. Oliveri, P. Luzi, L. Pacenti, I. Monciatti, S. Mannucci, M. C. De 
Nisi, M. Toscano, V. Malagnino, S. M. Falzarano, L. Pirtoli and P. Tosi (2007). "Protein and 
mRNA expression of autophagy gene Beclin 1 in human brain tumours." Int J Oncol 30(2): 
429-436. 
Mizushima, N. (2010). "The role of the Atg1/ULK1 complex in autophagy regulation." 
Curr Opin Cell Biol 22(2): 132-139. 
Mocellin, S. and D. Nitti (2008). "TNF and cancer: the two sides of the coin." Front Biosci 
13: 2774-2783. 
Moennikes, O., S. Loeppen, A. Buchmann, P. Andersson, C. Ittrich, L. Poellinger and M. 
Schwarz (2004). "A constitutively active dioxin/aryl hydrocarbon receptor promotes 
hepatocarcinogenesis in mice." Cancer Res 64(14): 4707-4710. 
Moore, M., T. R. Narasimhan, X. Wang, V. Krishnan, S. Safe, H. J. Williams and A. I. 
Scott (1993). "Interaction of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 12-O-
tetradecanoylphorbol-13-acetate (TPA) and 17 beta-estradiol in MCF-7 human breast cancer 
cells." J Steroid Biochem Mol Biol 44(3): 251-261. 
75  
 
Murayama, T., M. Inoue, T. Nomura, S. Mori and Y. Eizuru (2002). "2,3,7,8-
Tetrachlorodibenzo-p-dioxin is a possible activator of human cytomegalovirus replication in 
a human fibroblast cell line." Biochem Biophys Res Commun 296(3): 651-656. 
National Toxicology, P. (1982). "Carcinogenesis Bioassay of 2,3,7,8-Tetrachlorodibenzo-
p-dioxin (CAS No. 1746-01-6) in Swiss-Webster Mice (Dermal Study)." Natl Toxicol 
Program Tech Rep Ser 201: 1-113. 
Nebert, D. W., A. L. Roe, M. Z. Dieter, W. A. Solis, Y. Yang and T. P. Dalton (2000). 
"Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress 
response, cell cycle control, and apoptosis." Biochem Pharmacol 59(1): 65-85. 
Nezis, I. P. and H. Stenmark (2012). "p62 at the interface of autophagy, oxidative stress 
signaling, and cancer." Antioxid Redox Signal 17(5): 786-793. 
Nishino, I. (2006). "Autophagic vacuolar myopathy." Semin Pediatr Neurol 13(2): 90-95. 
North, C. M., R. B. Crawford, H. Lu and N. E. Kaminski (2010). "2,3,7,8-
tetrachlorodibenzo-p-dioxin-mediated suppression of toll-like receptor stimulated B-
lymphocyte activation and initiation of plasmacytic differentiation." Toxicol Sci 116(1): 99-
112. 
Paglin, S., T. Hollister, T. Delohery, N. Hackett, M. McMahill, E. Sphicas, D. Domingo 
and J. Yahalom (2001). "A novel response of cancer cells to radiation involves autophagy 
and formation of acidic vesicles." Cancer Res 61(2): 439-444. 
Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, 
DiProspero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, 
Hubbert CC, Yao TP, Baehrecke EH, Taylor JP. (2007). HDAC6 rescues neurodegeneration 
and provides an essential link between autophagy and the UPS. Nature 14;447(7146):859-63. 
Pattingre, S., A. Tassa, X. Qu, R. Garuti, X. H. Liang, N. Mizushima, M. Packer, M. D. 
Schneider and B. Levine (2005). "Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent 
autophagy." Cell 122(6): 927-939. 
Perlmutter, D. H. (2006). "The role of autophagy in alpha-1-antitrypsin deficiency: a 
specific cellular response in genetic diseases associated with aggregation-prone proteins." 
Autophagy 2(4): 258-263. 
Pesatori, A. C., D. Consonni, S. Bachetti, C. Zocchetti, M. Bonzini, A. Baccarelli and P. A. 
Bertazzi (2003). "Short- and long-term morbidity and mortality in the population exposed to 
dioxin after the "Seveso accident"." Ind Health 41(3): 127-138. 
Pirtoli, L., G. Cevenini, P. Tini, M. Vannini, G. Oliveri, S. Marsili, V. Mourmouras, G. 
Rubino and C. Miracco (2009). "The prognostic role of Beclin 1 protein expression in high-
grade gliomas." Autophagy 5(7): 930-936. 
Pohjanvirta, R. and J. Tuomisto (1994). "Short-term toxicity of 2,3,7,8-tetrachlorodibenzo-
p-dioxin in laboratory animals: effects, mechanisms, and animal models." Pharmacol Rev 
46(4): 483-549. 
76  
 
Powers, B. E., T. M. Lin, A. Vanka, R. E. Peterson, J. M. Juraska and S. L. Schantz (2005). 
"Tetrachlorodibenzo-p-dioxin exposure alters radial arm maze performance and hippocampal 
morphology in female AhR mice." Genes Brain Behav 4(1): 51-59. 
Proikas-Cezanne, T., S. Ruckerbauer, Y. D. Stierhof, C. Berg and A. Nordheim (2007). 
"Human WIPI-1 puncta-formation: a novel assay to assess mammalian autophagy." FEBS 
Lett 581(18): 3396-3404. 
Pua, H. H., I. Dzhagalov, M. Chuck, N. Mizushima and Y. W. He (2007). "A critical role 
for the autophagy gene Atg5 in T cell survival and proliferation." J Exp Med 204(1): 25-31. 
Ramadoss, P., C. Marcus and G. H. Perdew (2005). "Role of the aryl hydrocarbon receptor 
in drug metabolism." Expert Opin Drug Metab Toxicol 1(1): 9-21. 
Rehder, H., L. Sanchioni, F. Cefis and A. Gropp (1978). "[Pathological and embryological 
studies on abortion cases related to the Seveso accident]." Schweiz Med Wochenschr 
108(42): 1617-1625. 
Roman, B. L., B. G. Timms, G. S. Prins and R. E. Peterson (1998). "In utero and lactational 
exposure of the male rat to 2,3,7,8-tetrachlorodibenzo-p-dioxin impairs prostate 
development. 2. Effects on growth and cytodifferentiation." Toxicol Appl Pharmacol 150(2): 
254-270. 
Rosenfeldt, M. T. and K. M. Ryan (2011). "The multiple roles of autophagy in cancer." 
Carcinogenesis 32(7): 955-963. 
Rubinsztein, D. C., J. E. Gestwicki, L. O. Murphy and D. J. Klionsky (2007). "Potential 
therapeutic applications of autophagy." Nat Rev Drug Discov 6(4): 304-312. 
Safe, S., B. Astroff, M. Harris, T. Zacharewski, R. Dickerson, M. Romkes and L. Biegel 
(1991). "2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related compounds as 
antioestrogens: characterization and mechanism of action." Pharmacol Toxicol 69(6): 400-
409. 
Santamaria, R., F. Fiorito, C. Irace, L. De Martino, C. Maffettone, G. E. Granato, A. Di 
Pascale, V. Iovane, U. Pagnini and A. Colonna (2011). "2,3,7,8-Tetrachlorodibenzo-p-dioxin 
impairs iron homeostasis by modulating iron-related proteins expression and increasing the 
labile iron pool in mammalian cells." Biochim Biophys Acta 1813(5): 704-712. 
Santelli F, Boscaino F, Cautela D, Castaldo D, Malorni A (2006). "Determination of 
polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzo-p-furans (PCDFs) and 
polychlorinated biphenyls (PCBs) in buffalo milk and mozzarella cheese." Eur Food Res 
Technol 223:51–56. 
Saraon, P., K. Jarvi and E. P. Diamandis (2011). "Molecular alterations during progression 
of prostate cancer to androgen independence." Clin Chem 57(10): 1366-1375. 
Schaufler, K., P. Haslmayer, W. Jager, M. Pec and T. Thalhammer (2002). "The 
environmental toxin 2,3,7,8-tetrachlorodibenzo-p-dioxin induces cytochrome P450 activity in 
high passage PC 3 and DU 145 human prostate cancer cell lines." Int J Mol Med 9(4): 411-
416. 
77  
 
Schulman, C. C. (2000). "The aging male: a challenge for urologists." Curr Opin Urol 
10(4): 337-342. 
Shanmugam, M., S. K. McBrayer, J. Qian, K. Raikoff, M. J. Avram, S. Singhal, V. Gandhi, 
P. T. Schumacker, N. L. Krett and S. T. Rosen (2009). "Targeting glucose consumption and 
autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine." J Biol Chem 
284(39): 26816-26830. 
Shen, Y., D. D. Li, L. L. Wang, R. Deng and X. F. Zhu (2008). "Decreased expression of 
autophagy-related proteins in malignant epithelial ovarian cancer." Autophagy 4(8): 1067-
1068. 
Siegel, R., D. Naishadham and A. Jemal (2012). "Cancer statistics, 2012." CA Cancer J 
Clin 62(1): 10-29. 
Sorg, O., M. Zennegg, P. Schmid, R. Fedosyuk, R. Valikhnovskyi, O. Gaide, V. 
Kniazevych and J. H. Saurat (2009). "2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) poisoning 
in Victor Yushchenko: identification and measurement of TCDD metabolites." Lancet 
374(9696): 1179-1185. 
Srinivasan, S., R. Kumar, S. Koduru, A. Chandramouli and C. Damodaran (2010). 
"Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent 
prostate cancer." Apoptosis 15(2): 153-161. 
Staples, J. E., F. G. Murante, N. C. Fiore, T. A. Gasiewicz and A. E. Silverstone (1998). 
"Thymic alterations induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin are strictly dependent on 
aryl hydrocarbon receptor activation in hemopoietic cells." J Immunol 160(8): 3844-3854. 
Starkey, M.P., Scase, T.J., Mellersh, C.S., Murphy, S. (2005). "Dogs really are man's best 
friend--canine genomics has applications in veterinary and human medicine!" Brief Funct 
Genomic Proteomic 4(2):112-28. Review. 
Tanida, I., E. Tanida-Miyake, T. Ueno and E. Kominami (2001). "The human homolog of 
Saccharomyces cerevisiae Apg7p is a Protein-activating enzyme for multiple substrates 
including human Apg12p, GATE-16, GABARAP, and MAP-LC3." J Biol Chem 276(3): 
1701-1706. 
Tanida, I., T. Ueno and E. Kominami (2004). "LC3 conjugation system in mammalian 
autophagy." Int J Biochem Cell Biol 36(12): 2503-2518. 
Tanida, I., T. Yamaji, T. Ueno, S. Ishiura, E. Kominami and K. Hanada (2008). 
"Consideration about negative controls for LC3 and expression vectors for four colored 
fluorescent protein-LC3 negative controls." Autophagy 4(1): 131-134. 
Tenchini, M. L., C. Crimaudo, G. Pacchetti, A. Mottura, S. Agosti and L. De Carli (1983). 
"A comparative cytogenetic study on cases of induced abortions in TCDD-exposed and 
nonexposed women." Environ Mutagen 5(1): 73-85. 
Terman, A. and U. T. Brunk (2005). "Autophagy in cardiac myocyte homeostasis, aging, 
and pathology." Cardiovasc Res 68(3): 355-365. 
78  
 
Teske, E., E.C. Naan, E.M. van Dijk, E. Van Garderen, and J.A. Schalken. 2002. Canine 
prostate carcinoma epidemiological evidence of an increase risk in castrated dogs. Mol Cell 
Endocrinol 197:251-5. 
Thackaberry, E. A., Z. Jiang, C. D. Johnson, K. S. Ramos and M. K. Walker (2005). 
"Toxicogenomic profile of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the murine fetal heart: 
modulation of cell cycle and extracellular matrix genes." Toxicol Sci 88(1): 231-241. 
Thackaberry, E. A., B. A. Nunez, I. D. Ivnitski-Steele, M. Friggins and M. K. Walker 
(2005). "Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on murine heart development: 
alteration in fetal and postnatal cardiac growth, and postnatal cardiac chronotropy." Toxicol 
Sci 88(1): 242-249. 
Theobald, H. M. and R. E. Peterson (1997). "In utero and lactational exposure to 2,3,7,8-
tetrachlorodibenzo-rho-dioxin: effects on development of the male and female reproductive 
system of the mouse." Toxicol Appl Pharmacol 145(1): 124-135. 
Timms, B. G., R. E. Peterson and F. S. vom Saal (2002). "2,3,7,8-tetrachlorodibenzo-p-
dioxin interacts with endogenous estradiol to disrupt prostate gland morphogenesis in male 
rat fetuses." Toxicol Sci 67(2): 264-274. 
Vazquez-Martin, A., C. Oliveras-Ferraros and J. A. Menendez (2009). "Autophagy 
facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody 
trastuzumab." PLoS One 4(7): e6251. 
Vorderstrasse, B. A., J. A. Cundiff and B. P. Lawrence (2006). "A dose-response study of 
the effects of prenatal and lactational exposure to TCDD on the immune response to 
influenza a virus." J Toxicol Environ Health A 69(6): 445-463. 
Vorderstrasse, B. A., S. E. Fenton, A. A. Bohn, J. A. Cundiff and B. P. Lawrence (2004). 
"A novel effect of dioxin: exposure during pregnancy severely impairs mammary gland 
differentiation." Toxicol Sci 78(2): 248-257. 
Waters, D.J., Shen, S., Glickman, L.T., Cooley, D.M., Bostwick, D.G., Qian, J., Combs, 
G.F. Jr, Morris, J.S. (2005). "Prostate cancer risk and DNA damage: translational 
significance of selenium supplementation in a canine model." Carcinogenesis 26(7):1256-62. 
Epub Apr 7 
Wang, Y. J., H. Chang, Y. C. Kuo, C. K. Wang, S. H. Siao, L. W. Chang and P. Lin (2011). 
"Synergism between 2,3,7,8-tetrachlorodibenzo-p-dioxin and 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone on lung tumor incidence in mice." J Hazard Mater 186(1): 869-875. 
Warner, M., B. Eskenazi, P. Mocarelli, P. M. Gerthoux, S. Samuels, L. Needham, D. 
Patterson and P. Brambilla (2002). "Serum dioxin concentrations and breast cancer risk in the 
Seveso Women's Health Study." Environ Health Perspect 110(7): 625-628. 
Wei, Y., S. Sinha and B. Levine (2008). "Dual role of JNK1-mediated phosphorylation of 
Bcl-2 in autophagy and apoptosis regulation." Autophagy 4(7): 949-951. 
White, E. and R. S. DiPaola (2009). "The double-edged sword of autophagy modulation in 
cancer." Clin Cancer Res 15(17): 5308-5316. 
79  
 
Whitlock, J. P., Jr. (1990). "Genetic and molecular aspects of 2,3,7,8-tetrachlorodibenzo-p-
dioxin action." Annu Rev Pharmacol Toxicol 30: 251-277. 
Whitlock, J. P., Jr. (1999). "Induction of cytochrome P4501A1." Annu Rev Pharmacol 
Toxicol 39: 103-125. 
Winkler, S., Reimann-Berg, N., Murua Escobar, H., Loeschke, S., Eberle, N., Höinghaus, 
R., Nolte, I., and J. Bullerdiek (2006). "Polysomy 13 in a canine prostate carcinoma 
underlining its significance in the development of prostate cancer." Cancer Genet Cytogenet 
169(2):154-8. 
Wu J, Dang Y, Su W, Liu C, Ma H, Shan Y, Pei Y, Wan B, Guo J, Yu L. (2006). " 
Molecular cloning and characterization of rat LC3A and LC3B--two novel markers of 
autophagosome." Biochem Biophys Res Commun 6;339(1):437-42.  
Xie, G., Z. Peng and J. P. Raufman (2012). "Src-mediated aryl hydrocarbon and epidermal 
growth factor receptor cross talk stimulates colon cancer cell proliferation." Am J Physiol 
Gastrointest Liver Physiol 302(9): G1006-1015. 
Yang, W., J. H. Ju, K. M. Lee, K. Nam, S. Oh and I. Shin (2013). "Protein kinase B/Akt1 
inhibits autophagy by down-regulating UVRAG expression." Exp Cell Res 319(3): 122-133. 
Zafar, M. B. and M. K. Terris (2001). "Prostate cancer detection in veterans with a history 
of Agent Orange exposure." J Urol 166(1): 100-103. 
Zhao, C., S. Yin, Y. Dong, X. Guo, L. Fan, M. Ye and H. Hu (2013). "Autophagy-
dependent EIF2AK3 activation compromises ursolic acid-induced apoptosis through 
upregulation of MCL1 in MCF-7 human breast cancer cells." Autophagy 9(2): 196-207. 
 
 
 
 
80  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CURRICULUM VITAE 
 
 
 
 
 
 
 
81  
 
CURRICULUM VITAE 
 
 
NAME POSITION TITLE  
 Giovanna Elvira Granato PhD Student 
 
EDUCATION: 
 INSTITUTION AND LOCATION DEGREE YEAR(s) FIELD OF STUDY 
     
University of Naples, Italy D.V.M. 2008              Apoptosis and                       
                                                                                                                                          Virology 
University of Naples, Italy PhD stud 2010-13         Apoptosis,  
                                                                                                                                          Autophagy  
                                                                                                                                          and Virology  
Temple University, Philadelphia, PA USA                        PhD stud          2012-13        Apoptosis,   
                                                                                                                                          Autophagy                     
                                                                                                                                          and Cancer 
   
 
GENERAL INFORMATION: 
 
Name:                    Giovanna Elvira  
Family name:         Granato  
Place of birth:        Sarno (SA)  ITALY 
Date of birth:         October 29, 1983  
Nationality:            Italian  
Telephones:            +39 329-1168201  
Fax:                        +1 2678445616  
E-mail:                   giovanna.granato@unina.it  
Languages:             Italian (mother tongue); English (written and oral) 
 
Research and professional experience:  
 
2005-2008 Undergraduate Internship, laboratories of the Department of Pathology and Animal 
Health - Section of Infectious Diseases Faculty of Veterinary Medicine, University of Naples 
"Federico II" Italy. 
 
2008 Professional degree in D.V.M. 
 
June 2008 to January 2009, Postgraduate Internship, laboratories of the Department of Pathology 
and Animal Health - Section of Infectious Diseases Faculty of Veterinary Medicine, University of 
Naples "Federico II" Italy. 
 
April 2009 to February 2010, Postgraduate Scholarship, laboratories of the Department of 
Pathology and Animal Health - Section of Infectious Diseases Faculty of Veterinary Medicine, 
University of Naples "Federico II" Italy. 
 
82  
 
March 2010 to February 2012, PhD student, Veterinary Pharmacology, Toxicology and Clinical 
Sciences (XXV cycle) at the Department of Structures, Function and Biological Technologies-
University of Naples "Federico II” Italy. 
 
February 2012 to February 2013, PhD student, Sbarro Institute for Cancer Research and 
Molecular Medicine, Center for Biotechnology - Temple University - Philadelphia PA USA. 
 
 
References:  
 
Ciarcia Roberto, Professor, Department of Structures, Function and Biological Technologies - 
University of Naples "Federico II  
email: roberto.ciarcia@unina.it  
 
Florio Salvatore, Professor, Department of Structures, Function and Biological Technologies - 
University of Naples "Federico II”. 
email: salvatore.florio@unina.it  
 
Giordano Antonio, Professor and Director, Sbarro Institute for Cancer Research and Molecular 
Medicine, Center for Biotechnology - Temple University, PA - USA.  
email: giordano@temple.edu 
 
Pagnini Ugo, Professor, Department of Pathology and Animal Health - University of Naples 
"Federico II”. 
email: ugo.pagnini@unina.it  
 
Russo Giuseppe, Director of Cancer Systems Biology and SHRO eHealth Programs Sbarro Institute 
for Cancer Research and Molecular Medicine, Center for Biotechnology - Temple University, PA - 
USA.  
email: grusso@temple.edu 
 
 
 
Invited talks:  
 
Granato G.E., Fiorito F., Ciarcia R., De Blasio E., Barretta A., Marfè G., Iovane V., 
Florio S. 2,3,7,8-Tetraclorodibenzo-p-diossina anticipa l’attivazione di Nf-Kb durante 
l’infezione da Bovine Herpesvirus Tipo 1. Giornate Scientifiche del Polo delle Scienze e 
delle Tecnologie per la Vita. Napoli, November 25-26, 2010.  
 
Invited reviewer: 
 
2012- Present  Journal of Cellular Physiology  
 
 
 
 
 
83  
 
Publications: 
  
1. Montagnaro S., Ciarcia R., Pagnini F., De Martino L., Puzio M.V., Granato G.E., Avino F., 
Pagnini U., Iovane G., Giordano A.. Bovine herpesvirus type 4 infection modulates 
autophagy in a permissive cell line. J Cell Biochem. (2013) [Epub ahead of print]. 
2. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, 
Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes 
HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, 
Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, 
Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber 
BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC Jr, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, 
Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-
Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-
Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, 
Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar 
JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella 
M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, 
Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang 
RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, 
Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang 
HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey 
D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, 
Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan 
R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronjé MJ, Cuervo AM, Cullen JJ, Czaja 
MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De 
Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, 
Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Díaz-Araya G, Díaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-
Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, 
Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, 
Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, 
Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, 
Fanzani A, Farkas T, Farré JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Fésüs L, Feuer R, Figueiredo-Pereira ME, 
Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon 
EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, 
Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao 
GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, 
Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, Ghosh P, Giammarioli AM, Giatromanolaki AN, Gibson SB, Gilkerson RW, Ginger 
ML, Goncu E, Gongora C, Gonzalez CD, Gonzalez R, González-Estévez C, González-Polo RA, Gonzalez-Rey E, Gorbunov NV, Gorski 
S, Goruppi S, Gottlieb RA, Gozuacik D, Granato GE, Grant GD, Green KN, Gregorc A, Gros F, Grose C, Grunt TW, Gual P, Guan JL, 
Guan KL, Guichard SM, Gukovskaya AS, Gukovsky I, Gunst J, Gustafsson AB, Halayko AJ, Hale AN, Halonen SK, Hamasaki M, Han F, 
Han T, Hancock MK, Hansen M, Harada H, Harada M, Hardt SE, Harper JW, Harris AL, Harris J, Harris SD, Hébert MJ, Heidenreich 
KA, Helfrich MH, Helgason GV, Henske EP, Herman B, Herman PK, Hetz C, Hilfiker S, Hill JA, Hocking LJ, Hofman P, Hofmann TG, 
Höhfeld J, Holyoake TL, Hong MH, Hood DA, Hotamisligil GS, Houwerzijl EJ, Høyer-Hansen M, Hu B, Hu CA, Hu HM, Hua Y, Huang 
C, Huang J, Huang S, Huang WP, Huber TB, Huh WK, Hung TH, Hupp TR, Hur GM, Hurley JB, Hussain SN, Hussey PJ, Hwang JJ, 
Hwang S, Ichihara A, Ilkhanizadeh S, Inoki K, Into T, Iovane V, Iovanna JL, Ip NY, Isaka Y, Ishida H, Isidoro C, Isobe K, Iwasaki A, 
Izquierdo M, Izumi Y, Jaakkola PM, Jäättelä M, Jackson GR, Jackson WT, Janji B, Jendrach M, Jeon JH, Jeung EB, Jiang H, Jiang H, 
Jiang JX, Jiang M, Jiang Q, Jiang X, Jiang X, Jiménez A, Jin M, Jin S, Joe CO, Johansen T, Johnson DE, Johnson GV, Jones NL, Joseph 
B, Joseph SK, Joubert AM, Juhász G, Juillerat-Jeanneret L, Jung CH, Jung YK, Kaarniranta K, Kaasik A, Kabuta T, Kadowaki M, 
Kagedal K, Kamada Y, Kaminskyy VO, Kampinga HH, Kanamori H, Kang C, Kang KB, Kang KI, Kang R, Kang YA, Kanki T, 
Kanneganti TD, Kanno H, Kanthasamy AG, Kanthasamy A, Karantza V, Kaushal GP, Kaushik S, Kawazoe Y, Ke PY, Kehrl JH, Kelekar 
A, Kerkhoff C, Kessel DH, Khalil H, Kiel JA, Kiger AA, Kihara A, Kim DR, Kim DH, Kim DH, Kim EK, Kim HR, Kim JS, Kim JH, 
Kim JC, Kim JK, Kim PK, Kim SW, Kim YS, Kim Y, Kimchi A, Kimmelman AC, King JS, Kinsella TJ, Kirkin V, Kirshenbaum LA, 
Kitamoto K, Kitazato K, Klein L, Klimecki WT, Klucken J, Knecht E, Ko BC, Koch JC, Koga H, Koh JY, Koh YH, Koike M, Komatsu 
M, Kominami E, Kong HJ, Kong WJ, Korolchuk VI, Kotake Y, Koukourakis MI, Kouri Flores JB, Kovács AL, Kraft C, Krainc D, 
Krämer H, Kretz-Remy C, Krichevsky AM, Kroemer G, Krüger R, Krut O, Ktistakis NT, Kuan CY, Kucharczyk R, Kumar A, Kumar R, 
Kumar S, Kundu M, Kung HJ, Kurz T, Kwon HJ, La Spada AR, Lafont F, Lamark T, Landry J, Lane JD, Lapaquette P, Laporte JF, László 
L, Lavandero S, Lavoie JN, Layfield R, Lazo PA, Le W, Le Cam L, Ledbetter DJ, Lee AJ, Lee BW, Lee GM, Lee J, Lee JH, Lee M, Lee 
MS, Lee SH, Leeuwenburgh C, Legembre P, Legouis R, Lehmann M, Lei HY, Lei QY, Leib DA, Leiro J, Lemasters JJ, Lemoine A, 
Lesniak MS, Lev D, Levenson VV, Levine B, Levy E, Li F, Li JL, Li L, Li S, Li W, Li XJ, Li YB, Li YP, Liang C, Liang Q, Liao YF, 
Liberski PP, Lieberman A, Lim HJ, Lim KL, Lim K, Lin CF, Lin FC, Lin J, Lin JD, Lin K, Lin WW, Lin WC, Lin YL, Linden R, Lingor 
P, Lippincott-Schwartz J, Lisanti MP, Liton PB, Liu B, Liu CF, Liu K, Liu L, Liu QA, Liu W, Liu YC, Liu Y, Lockshin RA, Lok CN, 
Lonial S, Loos B, Lopez-Berestein G, López-Otín C, Lossi L, Lotze MT, Lőw P, Lu B, Lu B, Lu B, Lu Z, Luciano F, Lukacs NW, Lund 
AH, Lynch-Day MA, Ma Y, Macian F, MacKeigan JP, Macleod KF, Madeo F, Maiuri L, Maiuri MC, Malagoli D, Malicdan MC, Malorni 
W, Man N, Mandelkow EM, Manon S, Manov I, Mao K, Mao X, Mao Z, Marambaud P, Marazziti D, Marcel YL, Marchbank K, 
Marchetti P, Marciniak SJ, Marcondes M, Mardi M, Marfe G, Mariño G, Markaki M, Marten MR, Martin SJ, Martinand-Mari C, Martinet 
W, Martinez-Vicente M, Masini M, Matarrese P, Matsuo S, Matteoni R, Mayer A, Mazure NM, McConkey DJ, McConnell MJ, 
McDermott C, McDonald C, McInerney GM, McKenna SL, McLaughlin B, McLean PJ, McMaster CR, McQuibban GA, Meijer AJ, 
Meisler MH, Meléndez A, Melia TJ, Melino G, Mena MA, Menendez JA, Menna-Barreto RF, Menon MB, Menzies FM, Mercer CA, 
Merighi A, Merry DE, Meschini S, Meyer CG, Meyer TF, Miao CY, Miao JY, Michels PA, Michiels C, Mijaljica D, Milojkovic A, 
Minucci S, Miracco C, Miranti CK, Mitroulis I, Miyazawa K, Mizushima N, Mograbi B, Mohseni S, Molero X, Mollereau B, Mollinedo 
84  
 
F, Momoi T, Monastyrska I, Monick MM, Monteiro MJ, Moore MN, Mora R, Moreau K, Moreira PI, Moriyasu Y, Moscat J, Mostowy S, 
Mottram JC, Motyl T, Moussa CE, Müller S, Muller S, Münger K, Münz C, Murphy LO, Murphy ME, Musarò A, Mysorekar I, Nagata E, 
Nagata K, Nahimana A, Nair U, Nakagawa T, Nakahira K, Nakano H, Nakatogawa H, Nanjundan M, Naqvi NI, Narendra DP, Narita M, 
Navarro M, Nawrocki ST, Nazarko TY, Nemchenko A, Netea MG, Neufeld TP, Ney PA, Nezis IP, Nguyen HP, Nie D, Nishino I, Nislow 
C, Nixon RA, Noda T, Noegel AA, Nogalska A, Noguchi S, Notterpek L, Novak I, Nozaki T, Nukina N, Nürnberger T, Nyfeler B, Obara 
K, Oberley TD, Oddo S, Ogawa M, Ohashi T, Okamoto K, Oleinick NL, Oliver FJ, Olsen LJ, Olsson S, Opota O, Osborne TF, Ostrander 
GK, Otsu K, Ou JH, Ouimet M, Overholtzer M, Ozpolat B, Paganetti P, Pagnini U, Pallet N, Palmer GE, Palumbo C, Pan T, Panaretakis 
T, Pandey UB, Papackova Z, Papassideri I, Paris I, Park J, Park OK, Parys JB, Parzych KR, Patschan S, Patterson C, Pattingre S, Pawelek 
JM, Peng J, Perlmutter DH, Perrotta I, Perry G, Pervaiz S, Peter M, Peters GJ, Petersen M, Petrovski G, Phang JM, Piacentini M, Pierre P, 
Pierrefite-Carle V, Pierron G, Pinkas-Kramarski R, Piras A, Piri N, Platanias LC, Pöggeler S, Poirot M, Poletti A, Poüs C, Pozuelo-Rubio 
M, Prætorius-Ibba M, Prasad A, Prescott M, Priault M, Produit-Zengaffinen N, Progulske-Fox A, Proikas-Cezanne T, Przedborski S, 
Przyklenk K, Puertollano R, Puyal J, Qian SB, Qin L, Qin ZH, Quaggin SE, Raben N, Rabinowich H, Rabkin SW, Rahman I, Rami A, 
Ramm G, Randall G, Randow F, Rao VA, Rathmell JC, Ravikumar B, Ray SK, Reed BH, Reed JC, Reggiori F, Régnier-Vigouroux A, 
Reichert AS, Reiners JJ Jr, Reiter RJ, Ren J, Revuelta JL, Rhodes CJ, Ritis K, Rizzo E, Robbins J, Roberge M, Roca H, Roccheri MC, 
Rocchi S, Rodemann HP, Rodríguez de Córdoba S, Rohrer B, Roninson IB, Rosen K, Rost-Roszkowska MM, Rouis M, Rouschop KM, 
Rovetta F, Rubin BP, Rubinsztein DC, Ruckdeschel K, Rucker EB 3rd, Rudich A, Rudolf E, Ruiz-Opazo N, Russo R, Rusten TE, Ryan 
KM, Ryter SW, Sabatini DM, Sadoshima J, Saha T, Saitoh T, Sakagami H, Sakai Y, Salekdeh GH, Salomoni P, Salvaterra PM, Salvesen 
G, Salvioli R, Sanchez AM, Sánchez-Alcázar JA, Sánchez-Prieto R, Sandri M, Sankar U, Sansanwal P, Santambrogio L, Saran S, Sarkar 
S, Sarwal M, Sasakawa C, Sasnauskiene A, Sass M, Sato K, Sato M, Schapira AH, Scharl M, Schätzl HM, Scheper W, Schiaffino S, 
Schneider C, Schneider ME, Schneider-Stock R, Schoenlein PV, Schorderet DF, Schüller C, Schwartz GK, Scorrano L, Sealy L, Seglen 
PO, Segura-Aguilar J, Seiliez I, Seleverstov O, Sell C, Seo JB, Separovic D, Setaluri V, Setoguchi T, Settembre C, Shacka JJ, Shanmugam 
M, Shapiro IM, Shaulian E, Shaw RJ, Shelhamer JH, Shen HM, Shen WC, Sheng ZH, Shi Y, Shibuya K, Shidoji Y, Shieh JJ, Shih CM, 
Shimada Y, Shimizu S, Shintani T, Shirihai OS, Shore GC, Sibirny AA, Sidhu SB, Sikorska B, Silva-Zacarin EC, Simmons A, Simon AK, 
Simon HU, Simone C, Simonsen A, Sinclair DA, Singh R, Sinha D, Sinicrope FA, Sirko A, Siu PM, Sivridis E, Skop V, Skulachev VP, 
Slack RS, Smaili SS, Smith DR, Soengas MS, Soldati T, Song X, Sood AK, Soong TW, Sotgia F, Spector SA, Spies CD, Springer W, 
Srinivasula SM, Stefanis L, Steffan JS, Stendel R, Stenmark H, Stephanou A, Stern ST, Sternberg C, Stork B, Strålfors P, Subauste CS, 
Sui X, Sulzer D, Sun J, Sun SY, Sun ZJ, Sung JJ, Suzuki K, Suzuki T, Swanson MS, Swanton C, Sweeney ST, Sy LK, Szabadkai G, 
Tabas I, Taegtmeyer H, Tafani M, Takács-Vellai K, Takano Y, Takegawa K, Takemura G, Takeshita F, Talbot NJ, Tan KS, Tanaka K, 
Tanaka K, Tang D, Tang D, Tanida I, Tannous BA, Tavernarakis N, Taylor GS, Taylor GA, Taylor JP, Terada LS, Terman A, Tettamanti 
G, Thevissen K, Thompson CB, Thorburn A, Thumm M, Tian F, Tian Y, Tocchini-Valentini G, Tolkovsky AM, Tomino Y, Tönges L, 
Tooze SA, Tournier C, Tower J, Towns R, Trajkovic V, Travassos LH, Tsai TF, Tschan MP, Tsubata T, Tsung A, Turk B, Turner LS,  
Tyagi SC, Uchiyama Y, Ueno T, Umekawa M, Umemiya-Shirafuji R, Unni VK, Vaccaro MI, Valente EM, Van den Berghe G, van der 
Klei IJ, van Doorn W, van Dyk LF, van Egmond M, van Grunsven LA, Vandenabeele P, Vandenberghe WP, Vanhorebeek I, Vaquero EC, 
Velasco G, Vellai T, Vicencio JM, Vierstra RD, Vila M, Vindis C, Viola G, Viscomi MT, Voitsekhovskaja OV, von Haefen C, Votruba 
M, Wada K, Wade-Martins R, Walker CL, Walsh CM, Walter J, Wan XB, Wang A, Wang C, Wang D, Wang F, Wang F, Wang G, Wang 
H, Wang HG, Wang HD, Wang J, Wang K, Wang M, Wang RC, Wang X, Wang X, Wang YJ, Wang Y, Wang Z, Wang ZC, Wang Z, 
Wansink DG, Ward DM, Watada H, Waters SL, Webster P, Wei L, Weihl CC, Weiss WA, Welford SM, Wen LP, Whitehouse CA, 
Whitton JL, Whitworth AJ, Wileman T, Wiley JW, Wilkinson S, Willbold D, Williams RL, Williamson PR, Wouters BG, Wu C, Wu DC, 
Wu WK, Wyttenbach A, Xavier RJ, Xi Z, Xia P, Xiao G, Xie Z, Xie Z, Xu DZ, Xu J, Xu L, Xu X, Yamamoto A, Yamamoto A, 
Yamashina S, Yamashita M, Yan X, Yanagida M, Yang DS, Yang E, Yang JM, Yang SY, Yang W, Yang WY, Yang Z, Yao MC, Yao TP, 
Yeganeh B, Yen WL, Yin JJ, Yin XM, Yoo OJ, Yoon G, Yoon SY, Yorimitsu T, Yoshikawa Y, Yoshimori T, Yoshimoto K, You HJ, 
Youle RJ, Younes A, Yu L, Yu L, Yu SW, Yu WH, Yuan ZM, Yue Z, Yun CH, Yuzaki M, Zabirnyk O, Silva-Zacarin E, Zacks D, 
Zacksenhaus E, Zaffaroni N, Zakeri Z, Zeh HJ 3rd, Zeitlin SO, Zhang H, Zhang HL, Zhang J, Zhang JP, Zhang L, Zhang L, Zhang MY, 
Zhang XD, Zhao M, Zhao YF, Zhao Y, Zhao ZJ, Zheng X, Zhivotovsky B, Zhong Q, Zhou CZ, Zhu C, Zhu WG, Zhu XF, Zhu X, Zhu Y, 
Zoladek T, Zong WX, Zorzano A, Zschocke J, Zuckerbraun B..  
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy  
8(4):445-544 (2012). 
 
3. Ciarcia R., Damiano S., Fiorito F., Granato G., Pagnini F., Mastellone V., Iovane V., 
Alfano L., Valenti F., Florio S., Giordano A.. Hydrocortisone attenuates cyclosporin A-
induced nephrotoxicity in rats. J Cell Biochem. 113(3):997-1004 (2012). 
 
4. Fiorito F., Ciarcia R., Granato G. E., Marfe G., Iovane V., Florio S., De Martino L., 
Pagnini U.. 2,3,7,8-tetrachlorodibenzo-p-dioxin induced autophagy in a bovine kidney cell 
line. Toxicology. 18; 290(2-3):258-70 (2011). 
 
5. Ciarcia R., Granato G.E., Damiano S., Fiorito F., Russo R., Montagnaro S., Manco L., 
Florio S.. Hydrocortisone modulates the production of nitric oxide and the activity of the 
antioxidant enzymes in the kidney of rats treated with cyclosporine. Toxicol. Lett. 205S: S1-
S221 (2011). 
 
6. Damiano S., Ciarcia R., Scanni R., Granato G.E., Fiorito F., Capasso G., Florio S.. Renal 
proximal tubular reabsorption is reduced in adult rats treateed with csa:role of superoxide 
and Na+/H+ exchanger. Toxicol. Lett. 205S: S1-S221 (2011).  
 
85  
 
7. Granato G.E., Fiorito F., Ciarcia R., Marfe’ G., Cantiello A., Montagnaro S., Iovane V., 
Florio S.. Signs of cellular senescence induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in 
bovine cells. Toxicol. Lett. 205S: S159 (2011).  
 
8. Fiorito F., De Martino L., Granato G.E., Irace C., Di Pascale A., Maffettone C., Iovane V., 
Florio S.. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on iron metabolism during Bovine 
Herpesvirus 1 infection. Toxicol. Lett. 205S: S147 (2011).  
 
9. Santamaria R., Fiorito F., Irace C., De Martino L., Maffettone C., Granato G. E., Di 
Pascale A., Iovane V., Pagnini U. and Colonna A.. 2,3,7,8-tetrachlorodibenzo-p-dioxin 
impairs iron homeostasis by modulating iron-related proteins expression and increasing the 
labile iron pool in mammalian cells. Biochim Biophys Acta. 1813: 704-712 (2011).  
 
10. Fiorito F., Marfe’ G., Ciarcia R., Granato G.E., De Blasio E., Iovane G., Florio S., De 
Martino L. 2,3,7,8-Tetrachlorodibenzo-p-dioxin increases SIRT3 protein levels during 
Bovine Herpesvirus 1 infection. Toxicol. Lett. 196S: S195 (2010).  
 
11. Fiorito F., Ciarcia R., Granato G.E., De Blasio E., Marfe’ G., Iovane V., De Martino L., 
Florio S., Pagnini U. 2,3,7,8-Tetrachlorodibenzo-p-dioxin anticipates the activation of NF-
Kb during Bovine Herpesvirus 1 infection. Toxicol. Lett. 196S: S194 (2010).  
 
12. Fiorito F, Marfè G, Granato GE, Ciarcia R, De Blasio E, Tafani M, Florio S, De Martino L, 
Muzi G, Pagnini U, Giordano A. 2,3,7,8-Tetrachlorodibenzo-p-dioxin modifies Bovine 
herpesvirus 1 immediate-early protein (bICP0) expression and its nuclear/cytosolic 
localization during infection. J. Cell. Biochem. 111: 333-342 (2010).  
 
13. Fiorito F., Ciarcia R., De Blasio E., Granato G.E., Marfè G., Pelagalli A., Pero M.E., Florio 
S. and De Martino L. 2,3,7,8 Tetraclorodibenzo-p-dioxin induces cytoskeletal reorganization 
of Bovine cells during Bovine Herpesvirus 1 infection. J. Vet. Pharmacol. Therap. 32 
(S1):263 (2009).  
 
14. Fiorito F., Ciarcia R., De Blasio E., Granato G.E., Marfè G., D’Angelo D., Mastellone V., 
Florio S. and De Martino L. 2,3,7,8 Tetraclorodibenzo-p-dioxin modifies Bovine 
Herpesvirus 1 Immediately Early (BICP0) protein levels when infection starts. J. Vet. 
Pharmacol. Therap. 32(S1): 262-263 (2009).  
 
15. Fiorito F., Marfè G., De Blasio E., Granato G.E., Tafani M., De Martino L., Montagnaro 
S., Florio S., Pagnini U. 2,3,7,8-Tetrachlorodibenzo-p-dioxin regulates Bovine Herpesvirus 
type 1 induced apoptosis by modulating Bcl-2 family members. Apoptosis 13: 1243-1252 
(2008).  
 
 
International and National Conferences Proceedings 
 
1. Cantiello A., Fiorito F., Granato G.E., Pagnini U., Salvatore F. and Ciarcia R.. Modulation 
of Telomerase Activity, bTERT and c-Myc induced by 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
during Bovine Herpesvirus 1 infection in MDBK cells. The European Society of Toxicology 
In Vitro, Lisbon - Portugal, October 16-19, 2012. 
 
86  
 
2. Fiorito F., Ciarcia R., Cantiello A., , Granato G.E., Marfe' G., Iovane V., De Martino L. 
and Florio S.. Induction of both apoptosis and autophagy by 2,3,7,8-Tetrachlorodibenzo-p-
dioxin in mouse neuroblastoma (neuro-2A) cells. The European Society of Toxicology In 
Vitro, Lisbon - Portugal, October 16-19, 2012. 
 
3. Marfè G., Granato G. E., Fiorito F., Tafani M., Nizza S., Montagnaro S., Iovane V., 
Pagnini U., De Martino L.. Analysis of FOXO and Sirtuin proteins family in canine 
coronavirus type II - induced apoptosis. The 19th Euroconference on Apoptosis 
“Metabolism, Epigenetics and Death, 8th Training course on Concepts and Methods in 
Programmed Cell Death”, Stockholm – Sweden, September 14-17, 2011.  
 
4. Fiorito F., Ciarcia R., Granato G. E., Marfe’ G., Iovane G., Pagnini U., De Martino L.. 
Attenuation of ERK phosphorylation and down-regulation of c-Myc expression during 
BHV-1-induced apoptosis. The 19th Euroconference on Apoptosis “Metabolism, 
Epigenetics and Death, 8th Training course on Concepts and Methods in Programmed Cell 
Death”, Stockholm – Sweden, September 14-17, 2011.  
 
5. Granato G., Ciarcia R., Sasso S., Pagnini D., Fontana R., Di Maria D., Mettivier V., 
Mettivier L., Florio S.. Tratment with imatinib inhibits Nf-Kb and AP-1 activation and 
intracellular calcium levels INSP3 or ATP-induced in CML patients. The 16th Congress of 
European Hematology Association, London - United Kingdom, June 9-12, 2011.  
 
6. Granato G.E., Fiorito F., Ciarcia R., De Blasio E., Barretta A., Marfè G., Iovane V., Florio 
S. 2,3,7,8-Tetraclorodibenzo-p-diossina anticipa l’attivazione di Nf-Kb durante l’infezione 
da Bovine Herpesvirus Tipo 1. Giornate Scientifiche del Polo delle Scienze e delle 
Tecnologie per la Vita. Napoli, November 25-26, 2010.  
 
7. De Martino M., Granato G.E., Visone G.S., Caputo V., Rosato G., Montagnaro S.. 
Indagine molecolare sulla presenza di agenti virali gastroenterici in cani deceduti dell’ASL 
NA1. Giornate Scientifiche del Polo delle Scienze e delle Tecnologie per la Vita. Napoli, 
November 25-26, 2010.  
 
8. Desio G., De Martinis C., Montagnaro S., Granato G. E., Fiorito F., Roperto S., Fusco G., 
Guarino A., Rocco D., De Martino L., Iovane G., Pagnini U.. Serological survey of Bovine 
Herpesvirus-1, Bubaline Herpesvirus-1 and Bovine Viral Diarrhea Virus infections in 
buffalo herds of Caserta province. XXVI World Buiatrics Congress 2010, Santiago-Chile, 
November 14-18, 2010.  
 
9. Granato G.E., Fiorito F., Ciarcia R., De Martino L., Florio S., Pagnini U. 2,3,7,8-
Tetrachlorodibenzo-p-dioxin increases Bovine Herpesvirus 1 infection in Neuro-2a cells. 
Cellular Host-Pathogen Interaction Conference, Amsterdam - The Netherlands, September 
5-7, 2010. 
 
10. Ciarcia R., Navas L., Granato G.E., Fiorito F., Florio S. Aumento dello stress 
nitro/ossidativo in cagne con diverse neoplasie. LXIV National Conference S.I.S.Vet. Asti, 
September 7-10, 2010. 
 
11. Fiorito F., Ciarcia R., Granato G.E., Marfe’ G., De Martino L., Florio S., Iovane G. 2,3,7,8-
Tetrachlorodibenzo-p-dioxin modifies the levels of P21 and TERT proteins during Bovine 
87  
 
Herpesvirus 1 infection. Cellular Host-Pathogen Interaction Conference, Amsterdam-The 
Netherlands, September 5-7, 2010.  
 
12. Fiorito F., De Blasio E., Granato G.E., Cantiello A., Florio S., De Martino L. 2,3,7,8-
Tetrachlorodibenzo-p-dioxin modifies telomerase activity in Bovine Herpesvirus 1 
infection. The 8th International Cell Death Society Symposium “Cell Death in Infectious 
Diseases and Cancer”. Muldersdrift, Johannesburg, South Africa, June 5-8, 2009. 
 
13. Fiorito F., Granato G.E., De Blasio E., Marfè G., Arpenti C., De Martino L., Pagnini U. 
2,3,7,8-Tetrachlorodibenzo-p-dioxin anticipates the increase of p53 protein levels in Bovine 
Herpesvirus 1 induced apoptosis. The 8th International Cell Death Society Symposium 
“Cell Death in Infectious Diseases and Cancer”. Muldersdrift, Johannesburg, South Africa, 
June 5-8, 2009. 
 
14. De Blasio E., Fiorito F., Granato G.E., Cantiello A., Iovane V., Ciarcia R., Florio S. 
L’esposizione a 2,3,7,8-tetraclorodibenzo-p-diossina modifica i livelli della proteina Bovine 
Herpesvirus 1 immediate early (bICP0). Giornate Scientifiche del Polo delle Scienze e delle 
Tecnologie per la Vita. Portici, December 10-12, 2008. 
 
15. Granato G.E., Fiorito F., De Blasio E., Cantiello A., Arpenti C., De Martino L., Iovane G. 
2,3,7,8-Tetraclorodibenzo-p-diossina anticipa l’apoptosi indotta da Bovine Herpesvirus Tipo 
1 up-regolando l’attivazione delle caspasi. Giornate Scientifiche del Polo delle Scienze e 
delle Tecnologie per la Vita. Portici, December 10-12, 2008.  
 
16. Fiorito F., Granato G.E., De Blasio E., Longo M., Ciarcia R, Florio S. 2,3,7,8-
Tetraclorodibenzo-p-diossina anticipa l’apoptosi indotta da Bovine Herpesvirus tipo 1 
attraverso i membri della famiglia bcl-2. IIIa Meeting of Campani Pharmacologists. 
Benevento, September 26, 2008.  
 
17. Fiorito F., Granato G.E., De Blasio E., Longo M., Ciarcia R., Iovane V., Marfè G., 
Sinibaldi- Salimei P., De Martino L. 2,3,7,8-Tetrachlorodibenzo-p-diossina anticipates 
Bovine Herpesvirus type 1 induced apoptosis up-regulating caspase-3. Apoptosis World 
2008, From mechanism to applications. Luxembourg, January 23-26, 2008. 
 
18. Granato G.E., Fiorito F., De Blasio E., Ciarcia R., Damiano S., Arpenti C., Florio S. La 
2,3,7,8 tetraclorodibenzo-p-diossina induce apoptosi in cellule Madin Darby Bovine Kidney 
infettate con Bovine Herpesvirus tipo-1. Giornate Scientifiche del Polo delle Scienze e delle 
Tecnologie per la Vita. Naples, September 20-21, 2007.  
 
19. De Blasio E., Fiorito F., Granato G.E., Ciarcia R., Damiano S., Florio S. La 2,3,7,8 
tetraclorodibenzo-p-diossina modifica l'espressione della proteina immediate early bICP0. 
Giornate Scientifiche del Polo delle Scienze e delle Tecnologie per la Vita. Naples, 
September 20-21, 2007. 
 
 
 
 
 
 
88  
 
International and National Workshops and Courses: 
 
1. Certificate of participation at "Giornate Scientifiche del Polo delle Scienze e delle 
Tecnologie per la Vita" - University of Naples "Federico II" - Faculty of Pharmacy, 
September 10-12, 2007. 
 
2. Certificate of participation at "Giornate Scientifiche del Polo delle Scienze e delle 
Tecnologie per la Vita" - University of Naples "Federico II" - Portici, December 10-12, 
2008. 
 
3. Certificate of attendance at the conference "LE DIOSSINE: AMBIENTE E SALUTE”, 
Centro Congressi "Federico II" - Aula Magna Partenope, Naples, April 29 - 30 2009. 
 
4. Certificate of participation at the 11th International Congress of EAVPT, Leipzig 
(Germany), July 12 - 16, 2009. 
 
5. Certificate of participation at the seminar "Application Blotting and Imaging Systems" 
held by Bio-Rad, CNR of Naples, Naples, June 10, 2008. 
 
6. Certificate of participation at the "Giornata studio su Leishmaniosi canina: up-date sugli 
organi ed i tessuti coinvolti, vecchi e nuovi sintomi e nuove strategie terapeutiche" - Grand 
Hotel Salerno, December 14, 2008. 
 
7. Certificate of participation at the training course “Ecografia del Cane e del Gatto”, 
organized by Ordine dei Medici Veterinari Salerno - Castello Arechi, Salerno, September 
26 - 27, 2009. 
 
8. Certificate of participation at the “Aggiornamenti sulla TSE: Diagnosi ed epidemiologia” - 
IZSM, Portici, October 20, 2009. 
 
9. Certificate of participation at the “Autocontrollo, perchè è necessario parlarne ancora”, 
organized by Ordine dei Medici Veterinari Salerno - CREMOPAR, Eboli, October 22 - 
23/29 - 30, 2009. 
 
10. Certificate of participation at the “Paure e Fobie ed ansia da separazione del cane nuove 
normative legali”, organized by Ordine dei Medici Veterinari Salerno, November 15, 2009. 
 
11. Certificate of participation at the “Malattia Vescicolare Suina: Obiettivo Accreditamento” - 
Salone Conferenze Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, 
November 23, 2009. 
 
12. Certificate of participation at the “Emergenze Epidemiche: il Ruolo della Medicina 
Preventiva” - Centro Congressi dell’Ateneo Federico II of Naples, July 7, 2010. 
 
13. Certificate of participation in the XII International Congress of Toxicology, Barcelona - 
Spain, July 19 - 23 2010. 
 
14. Certificate of poster presentation  “2,3,7,8-Tetrachlorodibenzo-p-dioxin anticipates the 
activation of NF-kB during Bovine Herpesvirus 1 infection” - XII International Congress of 
Toxicology, Barcelona - Spain, July 19 - 23, 2010. 
89  
 
 
15. Certificate of participation at the Congress Cellular Host-Patogen Interaction - Amsterdam, 
The Netherlands, September 5-7, 2010. 
 
16. Certificate of participation at the Giornate Scientifiche del Polo delle Scienze e delle 
Tecnologie per la Vita - Naples, November 25-26, 2010. 
  
17. Certificate of participation at the 16th Congress of the European Hematology Association - 
London, United Kingdom, June 9 - 12, 2011. 
 
18. Certificate of participation in the 47th Congress of the European Societies of Toxicology - 
Paris, France,  August 28 - 31, 2011. 
 
Curriculum/Development 
 
1. Grant writing workshop, March 21th 2012, Temple University, Philadelphia, PA  
 
  
Informatics: 
1. ECDL: European Computer Driving Licence.(2003) 
Other: 
1. CERTIFICATE OF PERFORMER BLS-D - ASL SALERNO 1, Nocera Inferiore, July 14, 
2010. 
 
2. CERTIFICATE OF PERFORMER PBLS - ASL SALERNO 1 Nocera Inferiore, February 
22, 2011. 
 
 
 
 
 
 
 
 
 
90  
 
ACKNOWLEDGMENTS / RINGRAZIAMENTI 
Ci sono persone che vorrei ringraziare di cuore per aver reso stupende la mia vita e la mia 
esperienza di ricerca. 
 
Vorrei ringraziare: 
 
 i miei genitori e mio fratello, per il loro amore immenso e per il supporto in tutti gli 
obiettivi che ho voluto perseguire; 
 tutta la mia famiglia, per avermi donato sempre la serenita' che mi ha permesso di 
raggiungere molti traguardi; 
 Francesco, per il suo supporto quando le preoccupazioni erano tante e per la felicita' 
genuina quando le cose sono andate a mio favore; 
 la Dott.ssa Filomena Fiorito, per il suo sostegno continuo, l'incoraggiamento e 
l'orientamento lungo tutta la mia esperienza di ricerca pre e post-laurea (e' stato 
stupendo lavorare con te!); 
 la Dott.ssa Caterina Arpenti, per la sua bonta' e saggezza, e per l'assistenza tecnica che 
mi hanno permesso di perfezionare le mie competenze di laboratorio; 
 il Prof. Giuseppe Russo, per il suo sostegno, l'incoraggiamento e per essere stato la 
mia guida nell'ultimo anno di dottorato di ricerca (felicissima di averti incontrato 
lungo la  mia strada!); 
 il Prof Roberto Ciarcia, per avermi dato la possibilita' di intraprendere il dottorato di 
ricerca, esperienza unica che mi ha fatto crescere lavorativamente e non solo; 
 i Prof. Ugo Pagnini, Antonio Giordano, Salvatore Florio e Luisa De Martino, per 
essere stati un'ottima guida, per aver sostenuto le mie idee e per avermi concesso la 
libertà di poterle perseguire durante tutta la mia esperienza di ricerca; 
 i miei amici e colleghi: Emma De Blasio, Simona Sasso, Antonietta Cantiello, 
Annarosaria Marullo (in particolare ad Emma dico: grazie di cuore per esserci stata 
sempre!); 
 e ai miei amici che ogni giorno rendono felici le mie giornate ( le Valentine, Laura, 
Mena e....).  
Un ringraziamento perticolare va alle due persone che mi hanno aperto le porte dell'America: 
Prof. Antonio Giordano e Antonio Crispino, 
GRAZIE E' STATA 
UN'ESPERIENZA FANTASTICA! 
 
